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1 Summary 
Alveolar macrophages (AMs) are lung resident macrophages that reside in the lumen 
of small airways including alveoli. They play a critical role in lung homeostasis and 
maintain respiratory functions via surfactant clearance within the alveolar space. Like 
most other tissue-resident macrophages, AMs derive from fetal liver monocytes, 
which colonize the developing lung during embryogenesis and give rise to fully 
mature AMs perinatally. Recently, AM gene expression profile has been revealed and 
AM-specific transcription factor PPAR-γ has been identified. However, extracellular 
signaling mediators involved in AM development and maintenance have not been 
fully identified and the regulatory mechanisms related to AM genesis are still under 
investigation. It was previously shown that granulocyte macrophage colony 
stimulating factor (GM-CSF), an epithelial cell-derived cytokine is required for AM 
differentiation and Pparg expression, which is also critical for the development of 
AMs. Whether additional factors are involved in AM regulation is largely not known. 
Transforming growth factor-β (TGF-β), a multifunctional cytokine, is highly involved 
in cell fate determination and has been shown centrally involved in the genesis of 
Langerhans cells (LCs) and microglia activation. This indicates a possible role of 
TGF-β receptor (TGF-βR) signaling in regulating other myeloid cell populations. 
Since the role of TGF-βR signaling in the development of other macrophages is 
largely unknown, we investigated its function across different tissue-resident 
macrophages. 
Here we reported that AM differentiation and maintenance, in contrast to most other 
tissue macrophages, are also dependent on TGF-βR signaling. Specifically, 
conditional deletion of Tgfbr2, the non-redundant receptor for initiating TGF-βR 
signaling events, in mice at different time points halted the development and 
differentiation of AMs. Meanwhile, TGF-β was also found to be critical for AM 
homeostasis beyond the perinatal stage, as conditional tamoxifen-induced deletion of 
Tgfbr2 in adult R26CreER mice led to reduction of AMs in number. Further, we 
identified the source of TGF-β being AMs themselves, indicating an autocrine loop 
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that promotes AM self-maintenance. The transcriptomics analysis of Tgfbr2-deficient 
AMs perinatally revealed that TGF-β instructs AM signature and differentiation-
related gene expression. Mechanistically, we proposed that in parallel with GM-CSF, 
TGF-βR signaling results in upregulation of PPAR-γ, contributing to the 
establishment of fully differentiated AM identity.  
Altogether, we demonstrate that TGF-βR signaling is critical for the genesis, 
maturation and survival of AMs. These findings reveal an additional layer of 
complexity regarding the guidance cues, which govern the formation and diversity of 
tissue-resident macrophages. 
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2 Zusammenfassung   
Alveolarmakrophagen (AMs) sind die Gewebs-Makrophagen der Lunge und sind im 
Lumen der kleinen Atemwege sowie den Lungenbläschen sessil. Sie spielen eine 
kritische Rolle bei der Lungenhomöostase indem sie die Lungenfunktion durch die 
Beseitigung von Surfactant im Lungenraum aufrechterhalten. Wie die meisten 
anderen gewebespezifischen Makrophagen, entwickeln sich Alveolarmakrophagen 
aus den Monozyten der fetalen Leber, welche während der Embryogenese die sich-
entwickelnde Lunge besiedeln und zu Alveolarmakrophagen reifen. Erst kürzlich 
wurde PPAR-γ als spezifischer Transkriptionsfaktor für Alveolarmakrophagen 
identifiziert und die spezifische Genexpression der Alveolarmakrophagen aufgelöst. 
Jedoch ist noch nicht viel über die extrazellulären Faktoren, welche von den 
Alveolarmakrophagen sekretiert werden und die Regulationsmechanismen, denen die 
Identität der Alveolarmakrophagen unterliegt, bekannt. Die aktuelle Forschung 
fokussiert sich hauptsächlich auf den Granulozyten-Makrophagen-Kolonie-
stimulierenden Faktor (GM-CSF), ein Zytokin, welches vom Epithel sekretiert wird 
und wichtig für die Entwicklung der Alveolarmakrophagen und deren Pparg 
Expression ist. Allerdings ist noch nicht bekannt, ob zusätzliche Faktoren bei der 
Entwicklung der Alveolarmakrophagen eine Rolle spielen. Der ‚transformierende 
Wachstumsfaktor beta’ (TGF-β) ist für Gewebs-Makrophagen ein multifunktionelles 
Zytokin, welches für das Zellschicksal der Alveolarmakrophagen, die Entstehung der 
Langerhans-Zellen sowie die Aktivierung von Mikroglia von hoher Relevanz ist. 
Aufgrund dessen könnte der TGF-β Rezeptor Signalweg auch eine bedeutende Rolle 
für andere myeloide Zellen einnehmen. 
Wir konnten zeigen, dass Alveolarmakrophagen im Gegensatz zu vielen anderen 
gewebespezifischen Makrophagen vom TGF-β Rezeptor Signalweg abhängig sind. 
Eine konditionelle Deletion des TGF-β Rezeptor, dem nicht-redundanten TGF-β 
Rezeptor, zu unterschiedlichen Zeitpunkten verhinderte die Entwicklung und 
Differenzierung der Alveolarmakrophagen in Mäusen. TGF-β ist zudem auch nach 
der Geburt für die Homöostase der Alveolarmakrophagen wichtig, da eine 
Tamoxifen-induzierte Depletion des TGF-βR2 in adulten R26CreER Mäusen eine 
Reduktion der Alveolarmakrophagen verursachte. Als Quelle des TGF-β 
identifizierten wir Alveolarmakrophagen selbst, was auf eine autokrine 
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Selbstversorgung hindeutet. Die Transkriptom-Analyse der perinatalen TGF-βR2-
defizienten Alveolarmakrophagen verdeutlichte, dass TGF-β deren spezifische und 
Differenzierungs-bezogene Genexpression reguliert. Wir stellen die Hypothese auf, 
dass TGF-β ebenso wie GM-CSF die Expression von PPAR-γ, eines spezifischen 
Transkriptionsfaktors für Alveolarmakrophagen, reguliert.  
Abschließend konnten wir zeigen, dass der TGF-β Rezeptor Signalweg für die 
Entwicklung, Reifung sowie das Überleben von Alveolarmakrophagen von 
Bedeutung ist. Diese Erkenntnisse zeigen die Komplexität, welcher die Entstehung 
und Diversität der gewebespezifischen Makrophagen unterliegen. 	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3 Abbreviations 
AEC Alveolar epithelial cell 
AGM region Aorta, gonads, and mesonephros  
AIRE Autoimmune regulator 
AP-1 Activator protein 1 
BM Bone marrow  
CCR2 C-C chemokine receptor type 2  
cDC Conventional dendritic cell or Classical dendritic cell 
CDP Common dendritic cell progenitor 
CLP Common lymphoid progenitors  
cMoP Common monocyte progenitor 
CMP Common myeloid progenitor 
COPD Chronic obstructive pulmonary disease 
CREB Cyclic AMP-responsive element-binding protein  
CSF-1 Colony-stimulating factor 1 ( also known as M-CSF) 
CX3CR1 CX3 chemokine receptor 1 (also known as fractalkine receptor) 
DAMP Damage-associated molecular patterns  
DC Dendritic cell 
EAE Experimental autoimmune encephalomyelitis  
EMP Erythro-myeloid precursors  
FcγRI Fc-gamma receptor 1 (also known as CD64). 
FKBP12 12 kDa FK506-binding protein   
Flt3L Fms-like tyrosine kinase 3 ligand 
GARP Glycoprotein A repetitions predominant protein  
GM-CSF Granulocyte macrophage colony stimulating factor  
GMP Granulocyte-monocyte progenitor 
HSC Hematopoietic stem cell 
IFN Interferon  
IL-1β Interleukin-1 beta  
IL-23 Interleukin-23 
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IMF Interstitial macrophages  
iNOS Nitric oxide synthases  
IRF Interferon regulatory factor 
Itgam Integrin alpha M (also known as CD11b) 
Itgax Integrin alpha X ( also known as CD11c) 
iTreg Induced Treg 
JAK/STAT  Janus kinase-signal transducer of activation of transcription  
LAP Latency-associated peptide  
LC Langerhans cell 
LPS Lipopolysaccharides  
LTBP Latent TGF-β binding protein  
Ly6C Lymphocyte antigen 6 complex, locus C1 
MAPK Mitogen-activated protein kinase  
MdC Monocyte-derived cell  
MDP Macrophage dendritic cell progenitor 
MEP Megakaryocyte-erythrocyte progenitor 
MerTK Proto-oncogene tyrosine-protein kinase MER 
MHCI Major histocompatibility complex class I 
MHCII Major histocompatibility complex class II 
moDC Monocyte-derived dendritic cell 
MPS Mononuclear phagocyte system 
NF-κB Nuclear factor-κB  
NK cells Natural killer cells 
NLR NOD-like receptors  
nTreg Natural Treg 
PAMP Pathogen-associated molecular pattern 
PAP Pulmonary alveolar proteinosis  
PAR6 Partitioning defective 6  
pDC Plasmacytoid dendritic cell 
PRR Pattern recognition receptor 
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PU.1 Transcription factor PU.1 
RAG Recombinase-activating gene  
RLR RIG-I-like receptors  
Siglec-F Sialic acid-binding Ig-like lectin F 
TCR T cell receptor 
TdT Terminal deoxynucleotidyl transferase 
TGF-β Transforming growth factor beta  
TGF-βR TGF-β receptor  
TLR Toll-like receptors  
TNFα Necrosis factor alpha  
Treg Regulatory T cell 
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4 Introduction 
4.1 The Immune System 
The immune system is a host defense system against a full range of invading foreign 
agents including particles, viruses, bacteria and parasites, as well as diseased cells or 
tissue debris. Central processes in the immune response involve the recognition and 
clearance of non-self invading agents and abnormal self components. Dysregulation 
of the immune system is related to various types of human diseases. For example, a 
compromised or inactive immune system leads to immunodeficiency that is typically 
associated with recurring infections throughout life. The inability to distinguish non-
self and self might result in cancer or autoimmune diseases. In addition, the immune 
system also contributes to the proper development and normal homeostasis of host 
tissue1.  
The immune system can be divided into two parts: the innate immune system and the 
adaptive immune system. The innate immune system performs fast first-aid immune 
responses, while the adaptive immune system generates responses with a time lag but 
with memory and high specificity. From an evolutionary standpoint, innate immunity 
exists in all forms of life but only vertebrates have developed a complete adaptive 
immune system2. In mammals, both innate and adaptive immune systems are 
composed of cells, cytokines and humoral factors. They work in a coordinated and 
compensatory fashion to keep health and prevent infection. 
4.1.1 The Innate Immune System 
The innate immune system comprises three different parts throughout the human 
body: the anatomic barriers, the humoral compartment of innate immunity and innate 
immune cells. The anatomic barriers include epithelial cell-sealed surfaces, such as 
the skin, the gastrointestinal tract and the respiratory tract. These barriers prevent 
direct pathogen entry with intercellular tight junctions. They produce mucus and 
harbor microbiota to counteract the colonization of pathogens. Taking the lung as an 
example, the beating of cilia moves mucus towards the outside opening of the 
respiratory tract, trapping and flushing foreign particles away. Lung epithelial cells 
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secrete pulmonary surfactants and ‘antibiotics’ such as α-defensins and cathelicidin 
which further prevent invasions3.  
In humoral innate immunity, the complement system plays a major role. It is 
composed of more than 30 surface and plasma proteins that follow organized 
proteolytic cascades after recognition of pathogen-associated molecular patterns 
(PAMPs), pathogenic surfaces or antigen bound antibodies. Activated through three 
different pathways, the complement system converges into the assembly of C3 and C5 
convertase and generates core effectors: proinflammatory mediator anaphylatoxins 
(C4a/C3a/C5a), opsonins for opsonization of the surface of pathogens and the 
membrane attack complex for lysis of targeted surfaces.4  
The most dominant players in the innate immune system are the innate leukocytes: the 
myeloid cells including mononuclear phagocytes (monocytes, monocyte derived cells, 
dendritic cells (DCs) and macrophages), granulocytes (basophils, eosinophils, 
neutrophils and mast cells), and a few cell populations from the lymphoid lineage 
such as natural killer (NK) cells, innate lymphoid cells, and γδ T cells. Phagocytosis 
by monocytes, macrophages, neutrophils, DCs and mast cells of various invaders such 
as bacteria and parasites includes internalization, either for degradation in 
phagolysosomes or for antigen processing by antigen presenting cells, for example 
DCs, for initiating adaptive immune responses. Another immune mechanism to 
combat infections is to directly target infected cells for killing. NK cells induce 
cytotoxicity of target cells via secreting perforin and granzymes, activating Fas-
mediated caspase-dependent apoptosis or acting through antibody dependent cellular 
cytotoxicity. The killing activity of NK cells is regulated through the balance between 
inhibitory signals and activating signals. For example, viral infected host cells or 
tumor cells usually downregulate expression of the major histocompatibility complex 
class I (MHCI) molecule, which diminishes the inhibitory signal in NK cells and tips 
the balance towards the activating signals for killing.5 During the whole processes, 
innate leukocytes are activated to produce chemokines and cytokines that attract 
different players in the innate and adaptive immune compartment, which work 
cooperatively.  
The innate immune cells distinguish pathogens and abnormal fragments from healthy 
components through the recognition of conserved PAMPs from infectious microbes 
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or damage-associated molecular patterns (DAMPs) from host derived abnormal 
cellular events. Such pattern-based recognition is conducted by pattern recognition 
receptors (PRRs) present in different cell types, mainly Toll-like receptors (TLRs), C-
type lectin receptors, NOD-like receptors (NLR), RIG-I-like receptors (RLR) and 
DNA sensors 6. The patterns they can recognize cover a vast majority of pathogens, 
including lipopolysaccharides (LPS) from gram-negative bacteria, ssRNA, dsRNA 
and CpG rich DNA material from bacterial and virus, Flagellin from bacteria, β-
glucans from fungus, lipoteichoic acids from gram-positive bacteria and many 
bacteria specific lipomannans and lipoproteins. In general, TLRs are majorly 
responsible for recognizing PAMPs and DAMPs present in extracellular spaces or 
those that have been taken into the endosome, while NLRs detect mainly pathogenic 
material in the cytoplasm and RLRs sense cytoplasmic viral RNAs. Upon ligand 
binding, PPRs initiate intracellular signaling transduction and activate primarily the 
transcription factors nuclear factor-κB (NF-κB), interferon regulatory factor (IRF), 
activator protein 1(AP-1), and cyclic AMP-responsive element-binding protein 
(CREB) to induce the expression of inflammatory cytokines and type I interferons 
(IFN).7  
4.1.2 The Adaptive Immune System 
Usually, the activation of innate immunity is followed by adaptive immune system-
mediated responses that target antigens specifically and further keep the memory for 
the same antigen upon a second challenge. The two key players in adaptive immune 
system are T lymphocytes and B lymphocytes, which both make use of a vast 
diversity of antigen specific receptors. The diversity in T cell receptor (TCR) and B 
cell receptor (BCR) pool is generated via somatic DNA rearrangement and random 
chain pairing during cell development. Once they meet an antigen, the corresponding 
antigen specific B or T cells become activated and undergo clonal expansion, 
becoming numerous effector T cells for cytokine production, immune regulation or 
cytotoxicity induction or plasma cells for antibody production. 
T cells develop from common lymphoid progenitors (CLP) in the bone marrow (BM), 
which later migrate to the thymus where they mature into naive T cells. In the thymus 
the gene regions encoding TCR chains undergo somatic rearrangement of variable 
(V), diversity (D) and joining (J) fragments to generate mature VJ α-chains and VDJ 
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β-chains. This process is dependent on the lymphoid-specific recombinase-activating 
gene (RAG) 1 and RAG2 proteins for DNA elements cleavage and terminal 
deoxynucleotidyl transferase (TdT) for extra VDJ junction modification and diversity 
generation8. This generates a huge variety of T cell clones that later become 
CD4+CD8+ double positive. The double positive immature T cells are first positively 
selected in the thymic cortex for proper affinity of the TCR to self-major 
histocompatibility complex (MHC) class II (MHCII) molecules. During the positive 
selection, they become either CD4+ single positive if they are selected on MHCII 
molecules of cortical thymic epithelial cells or CD8+ single positive if they are 
selected on MHC class I (MHCI) molecules. The single positive immature T cells 
move to thymic medulla for negative selection so that self-reactive T cell clones are 
removed from the T cell pool under the control of a gene called autoimmune regulator 
(AIRE), expressed in medullary thymic epithelial cells.9 After positive and negative 
selection, naive mature T cells leave the thymus and migrate to secondary lymphoid 
tissues. When a naive CD4+ T cell encounters a cognate antigen presented on an 
MHCII molecule on the surface of antigen presenting cells or when a naive CD8+ T 
cell recognizes its corresponding antigen presented by MHCI molecules, naive T cells 
are activated and undergo clonal expansion and differentiate into effector T cells.  
Effector T cells, that is CD4+ T helper (Th) cells and CD8+ cytotoxic T cells, migrate 
in the periphery to the site of infection. T helper cells mainly secrete cytokines to 
boost and control the overall immune response as well as assist B cell activation. 
Cytotoxic T cells directly target cells bearing a specific antigen by MHCI molecules 
for killing. Effector T cells can remain, after pathogen clearance, as effector memory 
T cells in the periphery, and in the lymph node activated T cells can also stay as 
central memory T cells. CD4+ T cells can also develop into CD25+ Foxp3+ regulatory 
T cells (Tregs) either in the thymus as natural Tregs (nTregs), or in the periphery as 
induced Tregs (iTregs). They play a central role in modulating immune responses and 
regulating peripheral tolerance.10 
B cells develop in fetal liver and adult BM from CLPs. Similar to T cells, the 
maturation of B cells involves somatic rearrangement-mediated BCR repertoire 
formation. During antigen-dependent activation in peripheral lymphoid tissues, naive 
B cells become plasma cells after recognition of polymeric antigen or under the 
assistance of Th cells. The latter involves isotype switching, which generates BCRs 
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with the same antigen specificity but different effector functions and induces somatic 
mutation which leads to affinity maturation8. Plasma cells are professional antibody 
producing cells, releasing the secreted form of BCRs. Like T cells, the activated B 
cells can develop into memory cells for maintaining long-lived plasma cells, which 
constantly secrete antibodies and keep humoral immune surveillance11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  13	  
4.2 The Ontogeny and Function of Monocytes, Dendritic Cells and Tissue-
Resident Macrophages 
Monocytes, macrophages and DCs were classified together as the mononuclear 
phagocyte system (MPS) because they have previously been thought to share great 
similarity in morphology, ontogeny and function12. However, accumulating evidence 
shows that despite being mononuclear phagocytic cells, they have distinct functions in 
the immune system. Moreover, recent findings have overturned the old concept that 
BM-derived monocytes give rise to the rest of cell populations in the MPS. In fact, 
under non-inflammatory conditions, DCs and monocytes originate from two parallel 
branches, both of which are derived from macrophage dendritic cell progenitors 
(MDPs) in the BM. Under physiological condition, most macrophage populations are 
embryonically derived. Inflammation induced monocyte-derived cells (MdCs), 
typically referred to as monocyte-derived macrophages or monocyte-derived dendritic 
cells (moDCs), are phenotypically and functionally different from the 
conventional/classical (c)DCs or tissue-resident macrophages. (Figure.1.) 
 
Figure 1. Classification and ontogeny of mononuclear phagocytes. Mononuclear phagocytes are 
classified based on their ontogeny into three main groups:  embryonic-derived macrophages, 
monocytes/monocyte-derived cells (MdCs), and common dendritic cell precursor (CDP)-derived 
dendritic cells (DCs). Dependent on different sets of transcription factors during development, DCs are 
further divided into classical type 1 DCs (cDC1s), classical type 2 DCs (cDC2s) and plasmacytoid DCs 
(pDCs). Adapted from reference13 
4.2.1 Dendritic Cells 
DCs are sub-classified into cDCs and plasmacytoid dendritic cells (pDCs). pDCs are a 
rather separate population. They are specialized type I IFN producers after viral 
nucleic acids recognition and they can be easily distinguished from the rest of cells in 
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the MPS by B220 and Siglec-H expression14. Langerhans cells (LCs), the epidermal 
resident myeloid population, are often excluded when we mention cDCs because they 
are derived from embryonic precursors similar to tissue-resident macrophages and are 
therefore ontogenetically unrelated to cDCs 15,16. Experimentally, cDCs can be 
identified by the surface expression of MHCII and the integrin alpha X (Itgax, also 
known as CD11c), and the lack of macrophage markers such as proto-oncogene 
tyrosine-protein kinase MER (MerTK) and Fc-gamma receptor 1 (FcγRI, also known 
as CD64). 
cDCs are professional antigen presenting cells in the immune system. Like 
macrophages, they express PPRs and scavenger receptors to sense and take up non-
self particles, but they make use of the phagocytosis pathway to achieve their superior 
capability of antigen processing and presentation to naive T cells. By doing so, cDCs 
prime and reinforce T cell-mediated adaptive immune response to foreign antigens. 
On the other hand, they play a crucial role in inducing tolerance via the suppression of 
T cell responses and the control of regulatory T cell genesis and function17.  
cDCs are short-lived and constantly repopulated by BM-derived precursors. In the 
BM, all myeloid cells (DCs, monocytes, and granulocytes) are developed from 
common myeloid progenitors (CMP) which further give rise to megakaryocyte-
erythrocyte progenitors (MEPs) or granulocyte-monocyte progenitors (GMP)18. 
GMPs later develop into MDPs, which lose the potential to generate granulocytes and 
are committed to the DC and monocyte lineages only19,20. From MDPs, two lineages 
diverge: common monocyte progenitors (cMoP), which are unipotent in 
differentiating into monocytes, and common dendritic cell progenitors (CDP), which 
represent the first dedicated DC progenitor stage21. Depending on the presence of 
Fms-like tyrosine kinase 3 ligand (Flt3L) and the surface receptor Flt3 expression, 
CDPs are able to give rise to both pDCs and pre-DCs22. Pre-DCs leave the BM and 
seed all the tissues, which later fully differentiate into two cDC lineages: the cDC1 
and cDC2. Some evidence also indicates that the commitment to two cDC lineages 
happens at the CDP stage23.  
Typically, cDC1 refers to CD103+ cDC in nonlymphoid tissues and CD8+ cDCs in 
lymphoid tissues, while cDC2 refers to CD11b+ (also known as integrin alpha M, 
Itgam) cDC in both lymphoid and nonlyphoid tissues14,24. Experimentally, both 
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cDC1s and cDC2s are positive for MHCII and CD11c within the CD45+ 
compartment. The migratory DCs from non-lymphoid tissues to lymphoid tissues can 
be distinguished by their elevated MHCII expression and low expression of CD11c. 
Phenotypically, in many tissues cDC2s often express macrophage markers, such as 
CD172a, F4/80, and CX3CR1, that cDC1s lack. Most of the cDC1s are positive for 
CD24, CD26, Clec9a, langerin and the chemokine receptor XCR1, and have higher 
level of Flt3 expression than cDC2s14,24,25. More stringently, the cDC1 and cDC2 
subsets are determined based on the transcriptional regulators required for their 
development. cDC1s are dependent on transcriptional factor Batf3 and IRF8 and the 
inhibitor of DNA protein Id2 in their developmental processes26–29. On the contrary, 
the more heterogeneous cell population of cDC2s are independent of Batf3, IRF8 and 
Id2 but require IRF4, Zeb2, RelB and other different transcriptional factors for their 
development in different tissues14,30–33. Functionally, cDC1s present antigens 
preferably to CD8+ T cells via cross-presentation on MHCI and cDC2s have better 
capability in antigen presentation via MHCII14. cDC1s are found to be important in 
directing the differentiation of CD4+ T cells towards a Th1 phenotype via IL-12 
secretion and iTregs induction34. cDC2s promote Th2 responses as well as being the 
main IL-23 producers in mediating Th17 responses35–38. The same subsets of cDCs 
are present across different tissues. It is becoming evident that the distinct cDC1 or 
cDC2 ontogeny rather than their specific tissue microenvironment dictates the major 
differences that exist in these two cDC populations. 
4.2.2 Monocyte and Monocyte Derived Cells 
Monocytes are a short-lived cells and are constantly replenished by BM cMoPs 
independent of Flt3 21,39,40. In the blood stream, two populations exist within the 
monocyte compartment: Ly6Chi monocytes, which express high levels of lymphocyte 
antigen 6 complex, locus C1 (Ly6C) and Ly6Clo monocytes. Both populations express 
the colony-stimulating factor 1 (CSF-1; also known as macrophage colony-
stimulating factor, M-CSF) receptor (CSF-1R, M-CSFR), CD11b, and F4/80 positive. 
Ly6Chi monocytes, also referred to as classical monocytes, express additionally L-
selectin, CD62L, C-C chemokine receptor type 2 (CCR2), and intermediate levels of 
CX3 chemokine receptor 1 (CX3CR1, fractalkine receptor)41. Ly6Clo monocytes, 
known as patrolling monocytes, express low levels of Ly6C but high levels of 
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CX3CR1 and leukosialin (CD43). They lack CCR2 and CD62L expression. Ly6Chi 
monocytes are directly differentiated from cMoPs and exit from BM in a CCR2 
dependent manner42. In the blood, Ly6Chi monocytes give rise to Ly6Clo monocytes 
in a CSF-1R and CX3CR1/Nur77 dependent manner40,43,44.  
Functionally, Ly6Clo monocytes have been less studied. They are believed to be the 
counterpart of a ‘tissue-resident macrophage’ population in the blood, because of their 
prominent role in endothelial tissue homeostasis. It has been shown that Ly6Clo 
monocytes survey vessel integrity via phagocytosis of cellular debris and initiate 
tissue repair45,46. During inflammation and upon pathogenic infection, Ly6Chi 
monocytes enter tissues and differentiate into effector cells termed as MdCs, which 
are usually Ly6Chi but resemble cDCs or tissue-resident macrophage in expressing 
CD64, MHCII, and CD11c41. The mechanism in deciding the differentiation into 
moDCs or monocyte-derived macrophages is still under debate47. MdCs are quite 
heterogeneous populations in individual cases and sites of infection or inflammation. 
They are capable of synthesizing nitric oxide synthases (iNOS), and secreting 
cytokines such as tumour necrosis factor alpha (TNFα), Interleukin-1 beta (IL-1β), 
Interleukin-23 (IL-23) and IFN-γ48–50. MdCs can also acquire antigen-presenting 
properties and thus are able to prime T cells41,48. Tissue infiltrating Ly6Chi monocytes 
and MdCs are the main effector cells responsible for tissue damage during 
inflammation. For example during experimental autoimmune encephalomyelitis 
(EAE), disease progression correlates with the number of infiltrating moDCs51,52. In 
summary, monocytes and MdCs are important participants during inflammation and 
the pathogenesis of different infections and autoimmune diseases.  
4.2.3 Tissue-Resident Macrophages 
Macrophages are the resident populations present in all organs of the body. In general, 
unlike DCs and monocytes that are mainly involved in inflammation and adaptive 
immune responses, tissue-resident macrophages are specialized phagocytic cells 
dedicated in maintaining tissue homeostasis and integrity. Depending on which tissue 
they reside in, tissue-resident macrophages exhibit great heterogeneity in terms of 
development, maintenance and function24,53. Experimentally, most tissue-resident 
macrophages can be identified by the surface expression of CD11b, F4/80, CSF-1R, 
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MerTK and CD64 and a lack of Ly6C, though diversity of surface marker expressions 
exist among different tissue-resident populations24,53.  
As mentioned previously, the long-held dogma that BM-derived circulating 
monocytes migrate into peripheral tissues and differentiate into issue-resident 
macrophages has been largely revised. The majority of adult tissue-resident 
macrophage populations have embryonic precursors which seed the tissue before 
birth15,54. During embryogenesis, the hematopoietic system is gradually established in 
three waves (Figure 2). First, around embryonic day 7 (E7) early progenitors emerge 
from the blood islands of the extra-embryonic yolk sac, giving rise to primitive 
macrophages, erythroblasts and megakaryocytes. This stage is termed primitive 
hematopoiesis. The second wave, the transient definitive wave of erythro-myeloid 
precursors (EMPs), arise from the yolk sac hemogenic endothelium between E8.0 and 
E8.516.  This ‘late’ EMPs have the potential to give rise to erythroid and myeloid 
cells, but not to lymphoid lineages. After the blood circulation is established from 
E9.5, EMPs migrate into the fetal liver, where they give rise to different lineages, 
including fetal liver monocytes. Finally, definitive hematopoiesis starts from the 
intraembryonic hemogenic endothelium at E10.5. The immature hematopoietic stem 
cells (HSCs) first arise in the para-aortic splanchnopleura region and give rise to fetal 
HSCs in the aorta, gonads, and mesonephros (AGM) regions55,56. These precursors 
colonize both fetal liver and BM for the establishment of definitive hematopoiesis. 
From E12.5, the fetal liver becomes the major hematopoietic organ with precursors 
from both transient definitive and definitive hematopoietic waves55,56.  
The three waves of progenitors contribute differently to various tissue-resident 
macrophages along different time points in embryogenesis and adulthood. Yolk sac 
primitive macrophages are the only source of microglia throughout life since their 
residence in the brain from E9.557. In other organs, after primitive macrophages seed 
the tissues they remain dominant only between E10 and E13. Afterwards they are 
gradually replaced by fetal liver monocyte-derived macrophages, which are proposed 
to be originated from EMPs and with limited HSC involvement15,16. Despite this, 
circulating monocytes contribute to a various extent to different tissue-resident 
macrophages under normal homeostasis after birth. Microglia in the brain, LCs in the 
epidermis, alveolar macrophages in the lung, and splenic red pulp macrophages, self-
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renew locally and remain of embryonic origin without monocyte contribution55,57–60. 
Monocytes can differentiate into arterial macrophages and Kupffer cells in the liver 
within a short period after birth and, together with embryonic derived macrophages, 
self-maintain locally61,62. In contrast, macrophages in the gut, dermis, heart and 
pancreas are not capable of self-maintenance and are thus constantly repopulated by 
monocytes in adult63–67. Besides that, under certain conditions such as with severe 
pathological inflammation or upon lethal irradiation in a BM transplant setting, 
monocytes come to fill up the empty niche of tissue-resident macrophages.  
 
Figure 2. The three waves of embryonic hematopoiesis and their contribution to tissue-resident 
macrophages. Left: Illustration of yolk sac (YS), fetal liver (FL) and aorta-gonads-mesonephros 
(AGM) region in the mouse embryo. Right: Hematopoiesis emerges in three sequential programs.	  YS 
primitive progenitors give rise to the first wave of YS macrophages (red) at E7.5, which dominate in all 
tissues at E10.5 but only persist in the brain as microglia. Erythro-myeloid precursors (EMPs) that are 
generated at E8.5 in the hemogenic endothelium of the yolk sac initiate the second wave of 
hematopoiesis (orange). They give rise to FL monocyte which later seed every tissue with the 
exception of brain and differentiate into most adult resident macrophage populations. The third wave 
(blue) starts at E10.5 with the emergence of the hematopoietic stem cells (HSC) from the embryo 
proper hemogenic endothelium of the aorta-gonads-mesonephros (AGM) region. They can also 
generate fetal liver monocytes with limited contribution to tissue resident macrophages. Adapted from 
references16,68 
In general, by expressing Fc-receptors, complement receptors, PRRs, scavenger 
receptors and cytokine receptors, tissue-resident macrophages are capable of 
recognition, phagocytosis and degradation of pathogens and tissue debris, as well as 
sensing different stimuli and inducing immune responses and tissue repair69. In detail, 
despite having a similar developmental origin, tissue-resident macrophages mature 
into functionally different populations70 depending on diverse microenvironments and 
functional requirements of different organs. For example, adipose-associated 
macrophages mainly control insulin sensitivity and adaptive thermogenesis71,72. 
Alveolar macrophages are specialized in lung homeostasis and surfactant 
catabolism73. Microglia are highly involved in neuronal homeostasis and synaptic 
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remodeling74,75. Splenic red pulp macrophages and Kupffer cells support iron 
homeostasis as well as the clearance of blood carrying aged cells and debris76,77. Bone 
marrow macrophages play an important role in erythropoiesis and attaching 
hematopoietic stem cells to stem cell niches78–80. 
Common extrinsic and intrinsic factors critical for macrophage development and 
homeostasis have been identified. The development and survival of macrophages is 
largely dependent on CSF-1. Mice lacking CSF-1 show a severe reduction of most 
tissue-resident macrophage numbers81. The generation of primitive macrophages and 
hence microglia is a c-Myb expression-independent process, while subsequent 
hematopoietic waves require c-Myb. All primitive macrophages and adult tissue-
resident macrophages require transcription factor PU.1 (PU.1, encoded by Spi1), a 
pioneer transcription factor for their development and maintenance82,83. PU.1 is 
capable of binding to closed chromatin prior to macrophage lineage commitment and 
creating accessibility for additional trans-regulators84. These include lineage-defining 
transcription factors and stimuli-induced transcription factors, which together dictate 
the differentiation into the macrophage lineage and later the heterogeneity of 
macrophages in different tissue microenvironment, respectively85,86. The transcription 
factors c-Maf and MafB are key negative regulators of macrophage self-renewal87. A 
low expression of MafB and c-Maf in macrophages ensures the induction of genes 
including Myc, Klf2 and Klf4 with accessible enhancers and subsequently the self-
renewal capacity88. 
In recent years, unique gene expression profiles, specific transcriptional factors 
together with distinct sets of enhancers in each tissue macrophage population have 
been largely revealed53,85,89. These cell intrinsic factors include Sall1 for microglia, 
Peroxisome proliferator-activated receptor gamma (PPAR-γ) for alveolar 
macrophages, Gata6 for peritoneal macrophages, and Spi-C for splenic red pulp 
macrophages, which define the identity of each tissue-resident macrophage 
population.  
However, ontogeny alone could not fully explain why macrophages of similar origins 
have differential transcription factor gene expression. Evidence further indicates that 
the tissue microenvironment is non-redundant in shaping the identity of macrophages. 
Primitive macrophages, fetal liver monocytes, and adult monocytes can all develop 
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into functional ‘alveolar macrophages’ when they are transferred into the alveoli90. 
Terminally differentiated peritoneal macrophages can be reprogrammed by the lung 
microenvironment to exhibit alveolar macrophage-like phenotypes85. Altogether, 
identifying tissue related soluble factors and the underlying regulatory pathways for 
different macrophage populations become increasingly important for understanding 
macrophage development. For example, stromal cell-derived IL-34 is required by 
microglia for their maintenance and by LCs for their development and maintenance91. 
LCs are also dependent on TGF-β for inducing Id2 and Runx3 during their 
differentiation and homeostasis92,93. AMs on the other hand require granulocyte 
macrophage colony stimulating factor (GM-CSF, encoded by Csf-2) to maintain 
PPAR-γ expression for their development, survival and function60,94. Heme has been 
shown to induce Spi-c for red pulp macrophage development77,95. Retinoic acid 
elevates Gata6 expression and therefore contributes to the development of peritoneal 
macrophages96. Whether there are other tissue specific factors and how the overall 
regulatory network works remains elusive. 
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4.3 Alveolar Macrophages 
AMs are resident macrophages in the lung, which reside in the lumen of bronchi, 
bronchioles, and alveoli (Figure 3). Current studies did not distinguish macrophages 
that are exactly located in alveoli from those that are found in larger airways. AMs 
differ from a second macrophage population in the lung, the interstitial macrophages 
(IMF) that are located within the lung parenchyma. Phenotypically, AMs express 
common macrophage surface molecules like CD64, MerTK, and F4/80 and are 
negative for MHCII. In addition, they express high levels of CD11c and sialic acid-
binding Ig-like lectin F (Siglec-F) and low levels of CD11b, which distinguishes them 
from the Siglec-F-CD11b+ IMF60. Compared to other tissue-resident macrophages, 
AMs are kept in an immune suppressive state under homeostatic conditions and even 
during inflammation, they coordinate defense against infection and protection against 
tissue damage73,97,98. Loosely attached to alveolar epithelial cells (AECs), AMs 
closely interact with lung epithelium and alveolus microenvironment and thus exist as 
an indispensable cell type for pulmonary tissue homeostasis.   
                   
Figure 3. Overview of leukocytes and terminal airway structures in the healthy lung. Alveolar 
macrophages (AMs) reside in the airspaces next to either type I alveolar epithelial cells (AECIs) which 
are the sites of gas exchange and account for a majority of the total surface area of the lungs or next to 
type II alveolar epithelial cells (AECIIs) which are responsible for surfactant secretion. Inside the 
lumen of the healthy lung, AMs are the only dominant cell population, though eosinophils (not shown) 
and T cells can exist. Macrophages found in the larger airways (bronchi and bronchioles) and typically 
located within the mucous layer are also grouped into AMs. Beside AECs, lung epithelia also contain 
mucus-producing goblet cells and secretory non-ciliated Clara cells. In the interstitial space between 
the alveoli and the blood vessels, interstitial macrophages, T cells, dendritic cells and a sparse 
population of B cells (not shown) also reside. Commensal (and pathogenic) bacteria reside within the 
airway mucosa and in the alveoli. Adapted from reference73 
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4.3.1 The Function of Alveolar Macrophages  
Like other macrophages, AMs have the phagocytic ability to clear apoptotic cells, 
airborne agents, fungi and bacteria and have been shown to promote the defense 
against influenza virus infection94. Constantly exposed to the outside environment 
with excessive airborne particles, AMs have unique cell properties to prevent 
unnecessary inflammatory responses, resolve inflammation and avoid uncontrolled 
tissue injury. Early studies showed that lung macrophages secrete the cytokine TGF-β 
and suppress pulmonary immune responses by downregulating antigen-presentating 
functions of DCs99,100. It has been well established that depending on TGF-β and 
retinoic acids, AMs promote the generation of iTregs and hence promote airway 
tolerance towards innocuous inhaled antigens101.  The immune suppressive function 
of AMs is also mediated by inhibitory receptors on AMs that bind to the ligands 
presented by AECs or in the alveolar fluid. The interaction between CD200L on 
AECs and CD200R on AMs and the recognition of surfactant proteins SP-A and SP-
D by signal-regulatory protein SIRPα on AMs, negatively regulates TLR-induced 
pro-inflammatory responses73. Only combined PRR ligation that overrides the 
inhibitory signals will successfully activate AMs. For protecting tissues from injury 
and resolving inflammation, AMs upregulate Trem2 and mannose receptor (CD206) 
expression with a strengthened IL-10R ligation via an increased IL-10 supply from 
the extracellular space. These receptors on AMs cooperatively help to balance 
excessive IFN-γ, IL-1, TNF-α, and PRR downstream signaling73. Clinically, activated 
AMs or disappearance of resident AMs are often associated with pulmonary disorders 
such as allergic asthma and chronic obstructive pulmonary disease (COPD)102–104.  
Through removing inhaled particles, pathogens, matrix materials, apoptotic cells and 
tissue debris in an inflammation suppressive manner, AMs maintain the lung tissue 
integrity. Among them, one major role of AMs is the uptake and catabolism of 
surfactant, extracellular proteins and lipids that are secreted by type II AECs, which 
helps to lower the surface tension of the lung epithelium. Failure of AMs to do so 
leads to surfactant accumulation in the alveolar space and impairment of the 
respiratory function of the lung. In humans, this is termed pulmonary alveolar 
proteinosis (PAP) and has been recapitulated in Csf2-/- or Csf2rb-/- mice, which lack 
GM-CSF or its receptor and are hence devoid of AMs105,106.  Dysfunctional AMs have 
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also been implicated in PAP independent emphysema. Mice lacking αvβ6, an integrin 
that is expressed on the surface of respiratory epithelial cells and mediates latent 
TGF-β activation, will develop emphysema and lung inflammation107. 
4.3.2 The Developmental Pathway of Alveolar Macrophages 
AMs develop from fetal liver monocytes and these embryonically-derived AMs 
persist in the tissues throughout life in the steady state without the contribution of 
BM-derived precursors41,58. Briefly as previously described, fetal monocytes develop 
from late EMPs generated in the yolk sac at E8.5 and emerge in the fetal liver from 
E12.515,16. They begin to accumulate in the developing lung at E14.5 and then 
differentiate into immature AMs (preAMs), which mature into AMs postnatally60. 
During this process, fetal liver monocytes which are Ly6Chi, CD11bhi and F4/80+ 
down regulate Ly6C and CD11b when they differentiation into preAMs in the lung. 
These preAMs remain negative for Siglec-F and CD11c expression and only become 
fully mature after postnatal day (P)3 with high levels of Siglec-F and CD11c 
expression60. (Figure 4) 
          
Figure 4. The developmental pathway of AMs. AMs are fetal liver monocyte-derived and self-
maintain locally after birth. Fetal liver monocytes are generated around E12.5 from EMPs that emerge 
in the yolk sac at E8.5. They start to migrate to the developing lung at E14.5 and then differentiate into 
immature AMs (preAMs) at E18.5, which mature into AMs postnatally. During this course, fetal liver 
monocytes (Ly6Chi CD11bhi) down regulate Ly6C and CD11b when they differentiate into preAMs in 
the lung. These preAMs remain negative for Siglec-F and CD11c expression and only become fully 
mature postnatally with high levels of Siglec-F and CD11c expression. Afterwards, AMs self-renew 
locally throughout life. Induction of the AM-differentiation is dependent on GM-CSF. Ligation of GM-
CSFRs induces PPAR-γ expression in pulmonary fetal monocytes and instructs AM identity. Adapted 
from reference108. 
The genesis of AMs is highly dependent on GM-CSFR signaling as both Csf2-/- and 
Csf2rb-/- mice are devoid of AMs105,106. GM-CSFR signaling has been shown to be 
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essential for the differentiation of fetal monocytes into immature AMs perinatally and 
for the full maturation of AMs postnatally but not for the accumulation of fetal 
monocytes in the developing lung60,94. GM-CSF has been previously considered as a 
DC and pro-inflammatory cytokine as it is involved in the maintenance of 
homeostasis of cDC1 and some cDC2 populations in non-lymphoid tissues, and the 
genesis of moDCs in inflammatory settings109–112. How GM-CSF influences 
macrophages, in particular AMs, is now under investigation. In general, GM-CSF 
triggers a wide range of downstream signaling events including activation of the janus 
kinase-signal transducer of activation of transcription (JAK2/STAT5) pathway as well 
as activating the SRC family kinases, the PI3K pathways and the mitogen-activated 
protein kinase (MAPK) cascade113. It has been shown that GM-CSF-mediated AM 
differentiation and homeostasis are largely dependent on the macrophage pioneer 
transcription factor PU.1114. Equally important, GM-CSF influences the induction of 
the transcription factor PPAR-γ, a key factor for the transcriptional program specific 
to AMs94 (Figure 4). Independently of GM-CSF signaling, the transcription repressor 
Bach2 is critical in AM function and surfactant homeostasis of the lung115, indicating 
a more complicated regulatory mechanism than the current ‘one cytokine for one key 
transcription factor’ model. Whether during the development of AMs other cytokines 
are also involved is largely unknown and worth to be investigated. 
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4.4 The TGF-βR Signaling 
The transforming growth factor beta (TGF-β) receptor (TGF-βR) signaling pathway is 
one of the most ancient and prevailing pathways found in metazoans. The emergence 
of orthologues of its core players dates back to the earliest animal species, Trichoplax 
adhaerens (‘flat animals’, a free-living organism with the simplest structure in all 
multicellular animals)116. It has fundamental and diverse functions in regulating the 
survival, pluripotency, growth, division and differentiation of embryonic stem cells, 
lineage progenitors and differentiated cells117. At tissue and organ levels it controls 
morphogenesis, homeostasis and regeneration in both dose-dependent and context-
dependent manner117.  
In general, the TGF-βR signaling pathway is initiated with the binding of TGF-β to 
two Type II receptor TGF-βR2 molecules at the surface of the cell membrane, which 
induces the formation of a hetero-tetrameric complex between one TGF-βR2 
homodimer and one homodimer of the Type I receptor TGF-βR1. Both TGF-βR1 and 
TGF-βR2 are receptor serine/threonine kinases. In the complex, TGF-βR2 
phosphorylates TGF-βR1, which activates the kinase activity of TGF-βR1 with the 
dissociation of the 12 kDa FK506-binding protein (FKBP12). The activated TGF-βR1 
can bind and phosphorylate Smad2 or Smad3 downstream. Phosphorylated Smad2/3 
bind to Smad4 and, as a complex, they translocate to the nucleus. Cooperating with 
different partner transcription factors, the Smad complex is directed to the promoter 
region of different sets of genes, regulating their transcriptional activities118. 
4.4.1 The Complexity in TGF-βR Signaling 
The TGF-β-TGF-βR1/2-Smad axis mainly regulates cell differentiation and inhibits 
cell proliferation in embryonic development and tissue homeostasis. Beyond the 
conventional TGF-β pathway, regulations and bifurcations occur at multiple levels in 
its signaling transduction. This generates large complexity in signaling and 
phenotypic outcomes after receptor-ligand binding. 
4.4.1.1 The extracellular activation of the TGF-β cytokine 
The active TGF-β cytokine is in the form of a 25-kd disulfide-linked dimer. 
Interestingly, in the extracellular space the TGF-β dimers usually remain inactive and 
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stored in large latent forms (Figure 5). TGF-β is synthesized as a much larger 
precursor peptide that is composed of the small C-terminal mature TGF-β fragment, a 
rather large N-terminal fragment namely the latency-associated peptide (LAP), and a 
signal peptide later being removed after directing precursor peptide into endoplasmic 
reticulum. In the lumen of endoplasmic reticulum, TGF-β precursors are assembled 
into a dimer. Either before or after secretion, the LAP and the mature TGF-β cytokine 
part require being cleaved from each other by the endoprotease furin for activation. 
After cleavage, the TGF-β part remains non-covalently attached and folded into the 
LAP region and thus being prevented from interacting with its receptors after 
secretion. The whole complex is defined as the small latent complex. The LAP region 
facilitates the interaction and binding between the small latent complex and integrins. 
In most cell types, the LAP region is associated with the latent TGF-β binding protein 
(LTBP), together forming the large latent complex with the TGF-β cytokine. LTBP 
mediates the interaction and attachment of the large latent complex with extracellular 
matrix.119 
To release the mature TGF-β dimer from the latent complex, a large variety of 
potential mediators locate in the cell surface and extracellular space. These include 
extracellular matrix protein, e.g. Thrombospondin 1, for dissociating the latent 
complex120–122; glycosidases, e.g. neuraminidase on the surface of influenza virus123; 
proteases, e.g. metalloproteases MMP9 and MMP14124 and integrins, dendritic cell 
surface bound αvβ8 and epithelial cell surface bound αvβ6 for activating TGF-β for T 
cells and macrophages respectively107,125,126.  
Despite these complex interactions, the basic principle of TGF-β maturation is simple: 
an enzymatic digestion- or interaction-based conformational change that switches the 
latent complex into an open form to free the TGF-β dimer. Such a process can be 
highly content specific, owing to the different, overlapping or even contradictory 
regulators that exist in the whole system. For example Fibrillin 1 anchors LTBPs to 
fibers in the extracellular matrix and inhibits TGF-β activation in certain tissues. 
Mutations found in LTBPs suppress TGF-β ligand activation in lung and bone 
development. On the contrary, mutations in human Fibrillin 1 lead to excessive TGF-
β activation in lung and aortic aneurysms119. As another example, glycoprotein A 
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repetitions predominant protein (GARP), is found to be restricted to Foxp3+ Tregs and 
counteracts the binding of LTBP to TGF-β127.  
                          
Figure 5. Processing and activation of TGF-β. Tgfb genes encode an N-terminal latency-associated 
peptide (LAP) and a C-terminal mature cytokine that form dimers after being synthesized. The LAP 
and the mature TGF-β cytokine are cleaved from each other by the enzyme furin but remain non-
covalently associated after secretion. The LAP region folds around the mature cytokine, blocking its 
access to the receptors, and this is termed the small latent complex. In some cells, the small latent 
complex can associate with latent TGF-β binding protein (LTBP) via interactions with LAP, forming 
the large latent complex which facilitates the interaction with extracellular matrix. Once the LAP has 
been digested enzymatically or removed via interaction-based conformational change, the mature TGF-
β is released and becomes active for receptor binding. Adapted from reference119.  
 
4.4.1.2 The divergence in TGF-βR signaling transduction  
After being released from the latent complex, TGF-β ligand binds exclusively to 
TGF-βR2 and vice versa. Evidence exists that instead of TGF-βR1, in certain cell 
types or with high TGF-β concentration, TGF-βR2 could bind and activate ALK1 or 
ALK2, both BMP family receptors, which lead to the phosphorylation and activation 
of Smad1/5 and subsequently the bifurcation into the BMP signaling pathway118.  
TGF-β can signal without Smad-mediated transcriptional regulation, that is, in a non-
canonical fashion. For example, in non-canonical TGF-βR signaling pathway, 
phosphorylated TGF-βR directly regulates signaling events in MAPK/ERK pathways 
and PI3K/AKT pathways in a Smad-independent manner, as one of the key mediators 
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in cell growth, proliferation and survival118. Also, TGF-β could directly signal 
through TGF-βR2 via phosphorylation of the cell polarity regulator, partitioning 
defective 6 (PAR6), in epithelial to mesenchymal transition for RhoA GTPase 
degredation or in axon formation in neurons128,129. Further, pSmad3 could serve as a 
Drosha component in promoting the biogenesis of microRNAs that harbor Smad 
binding sites130,131. (Figure 6.) 
 
Figure 6. The canonical TGF-βR signaling and its divergence and regulation. In canonical TGF-
βR signaling (indicated by black arrows), the binding of active TGF-β to TGF-βR2 dimers induces the 
phosphorylation and activation of TGF-βR1 dimers, which bind to and phosphorylate Smad2 or 
Smad3. Phosphorylated Smad2/3 (pSmad2/3) bind to Smad4 and, as a complex, they translocate to the 
nucleus and initiate transcription regulation of target genes together with other transcription factors. 
Dependent on the status of the cell, many other signaling events can happen (indicated by grey arrows): 
1. signaling directly through TGF-βR2 via PAR6; 2. signaling via MAPKs and PI3K pathways 
independent of Smads proteins; 3. variations of the signaling activity due to regulations and 
modifications on Smad proteins; 4. controlling miRNA biogenesis via Smad protein directed Drosha 
complex assembly; 5. Smad protein associated epigenetic regulators recruitment. Adapted from 
reference118. 
 
4.4.1.3 Regulators and transcription initiation 
The activity of pSmad itself is highly modulated by ubiquitination-mediated 
degradation, kinase activity, and other modifications, and serves as a key target in 
regulating TGF-βR signaling. For example, Smads can be ubiquitinated and degraded 
via Smad7-mediated Smurf recruitment, with competition from deubiquitases like 
USP15132,133. In response to other growth factors, extracellular stress and cell intrinsic 
status, components from ERK/MAPK signaling and the cell cycle are integrated into 
TGF-βR signaling through modification of pSmad118.   
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In the canonical pathway, Smad proteins not only influence the transcription of active 
genes via cooperations with diverse sets of transcription factors and cofactor, but they 
also shape the epigenetic state of target genes. Smad proteins recruit histone acetyl 
transferases for general transcription activation. Through binding the partners 
TGIF1/2 mediated C-terminal-binding protein and histone deacetylases recruitment, 
Smad proteins suppress gene accessibility via histo-deacetylation. With TGF-β 
stimulation, locus of gene CDNK2B is de-methylated at its promoter region and 
becomes active after SMAD4-SMAD2/3-FOXO-mediated DNA excision repair 
complex recruitment118,134,135. 
Overall, the response of a given cell type to TGF-βR signaling is determined by 
defined input signals and the compositions of signaling network machinery in that 
cell, combinations of transcription factors, cofactors and epigenetic regulators that are 
actually expressed in this particular cell type and their interaction with the Smad 
complex, and further the established general epigenetic status of the cell and the 
accessibility of a given locus, that is, whether the chromatin is open for transcriptional 
regulation initiated by TGF-βR signaling.  
4.4.2 The Role of TGF-βR Signaling in the Immune System 
TGF-β ligands are widely and highly expressed during embryogenesis in a cell-
specific and time-specific manner and they are also detectable in adult in the steady 
state. Of the three highly homologous TGF-β isoforms (TGF-β1, TGF-β2, TGF-β3), 
TGF-β1 is the predominant isoform within the immune system118,136,137. 
The importance of TGF-β signaling in embryogenesis and its regulatory role in the 
immune system has been revealed from early studies on Tgfbr2-/- mice and Tgfb1-/- 
mice. Tgfbr2-/- embryos and one half of the Tgfb1-/- embryos die at E10.5 due to 
hematopoietic and vasculo-genetic defects in the yolk sac138,139. The other half of 
Tgfb1-/- embryos survive until a few weeks after birth and then die because of a 
wasting syndrome and multifocal inflammatory disease138,140,141. It was shown that 
TGF-β is responsible for NK cell immaturity during their ontogeny142. Studies on T 
cells suggest that TGF-β signaling affects many aspects of T cells, for example on 
CD4+ and CD8+ T cell survival, CD8+ T cell, NKT cell and nTreg cell development, 
and Th1, Th2, Th17 and iTreg differentiation119,143.  
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TGF-βR signaling is widely involved in stem cell function and differentiation. Within 
the hematopoietic system, TGF-βR signaling maintains HSCs in quiescence and 
hence prevents their exhaustion. During the early differentiation of HSCs, TGF-βR 
signaling is a stimulant for myeloid-biased HSC proliferation as well as an inhibitor 
of lymphoid-biased HSC144. For the genesis of yolk sac derived precursors, the role of 
TGF-βR signaling remains largely unknown. Due to lethality in TGF-βR signaling 
deficient mice, the exact function of TGF-βR signaling cannot be identified from the 
large influence from its impact on organogenesis.  
Regarding the myeloid system, TGF-βRs are broadly expressed by DCs and 
macrophages. According to the ImmGen data53, Tgfbr1 and Tgfbr2 are expressed at 
diverse levels on different DC subsets and tissue-resident macrophage populations. 
For example LCs, microglia, AMs, small intestine lamina propria and serosal 
macrophages and kidney CD11b+ DCs exhibit high Tgfbr2 expression. Mice in which 
Tgfbr2 was specifically deleted from DCs (CD11cCreTgfbr2fl/fl) showed an altered 
Treg phenotype and multi-organ autoimmune disease caused by ‘proinflammatory' 
DCs. This reveals a direct effect of TGF-β signaling on DCs to control 
autoimmunity145. Recently, studies have shown that TGF-βR signaling regulates 
CD103+CD11b+ DC development in the intestine, indicating a role of TGF-β in DCs 
under the steady state condition. The development and maintenance of LCs, the 
resident embryonically-derived myeloid cells of the skin, is dependent on TGF-βR 
signaling92,93.TGF-β stimulation allows PU.1 to directly induce Runx3 and Id2, and 
the expression of the latter prevents B cell-related gene expression in a progenitor 
cell.144,146. TGF-β has also been shown to be critical for microglial development and 
influences microglia gene signature expression and activation in vitro and in 
vivo147,148.  
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5 Aims 
In the past few years, great effort has been made to uncover signature genes, unique 
transcriptional factors and enhancer landscapes of different tissue-resident 
macrophages. However, extracellular signaling mediators that govern the differential 
gene expressions during macrophage development are largely unknown. TGF-β is a 
cytokine with versatile effects on cell fate determination. Therefore, we aimed to 
investigate the role of TGF-β across different tissue-resident macrophage populations 
during their development, maturation and homeostasis.  
Specifically, we focused on unraveling the role of TGF-βR signaling in alveolar 
macrophages (AMs), as they highly express TGF-βRs in the steady state. Using 
mouse models with different Cre recombinase-dependent Tgfbr2 locus deletion, we 
determined the role of TGF-βR signaling on AMs in their differentiation, maturation, 
self-maintenance and function in the steady state. In addition, we aimed to identify the 
source of TGF-β that is required by AMs in these processes. 
Furthermore, we investigated the downstream effects of TGF-βR signaling in AMs. 
By comparing gene expression levels in TGF-βR deficient AMs versus intact AMs, 
we aimed to gain insight into the relationship among AM-specific genes, the ‘AM 
cytokine’ GM-CSF and TGF-βR signaling. 
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6 Results 
6.1 AMs are Dependent on TGF-βR Signaling  
To investigate the role of TGF-βR signaling in the development of tissue 
macrophages, we analyzed ItgaxCreTgfbr2fl/fl mice, in which Tgfbr2 is deleted in 
CD11c+ cells including DCs and macrophages in the lung, the small intestinal lamina 
propria and the kidney. We found that at 4 weeks of age, AMs were completely 
absent in ItgaxCreTgfbr2fl/fl mice (Figure 7A-B). Conversely, lung interstitial 
macrophages (CD11c+MHCII+CD11b+CD24-CD64+)149 and DCs were not affected 
(Figure 7B-C). Other CD11c+ tissue macrophages including kidney and small 
intestinal lamina propria macrophages, were also present at normal frequencies in 
ItgaxCreTgfbr2fl/fl mice, while LCs were largely absent, consistent with their known 
dependence on TGF-βR signaling (Figure 8A). ItgaxCreTgfbr2fl/fl mice develop multi-
organ autoimmune disease due to deletion of Tgfbr2 on DCs starting at the age of 4-5 
weeks145. Indeed, at 4 weeks of age we already observed increased invasion of 
monocytes and neutrophils into most tissues in ItgaxCreTgfbr2fl/fl mice (data not 
shown). Thus, to rule out that the observed AM phenotype is a result of local 
inflammation, analyses were performed at earlier time points at which the 
ItgaxCreTgfbr2fl/fl mice appear clinically and phenotypically healthy. We found that at 
two weeks of age, AMs were already absent (Figure 7A).  
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Figure 7. AMs are dependent on TGF-βR signaling. (A-C) Flow cytometry of lung cells derived 
from ItgaxCreTgfbr2fl/fl mice and control littermates (Tgfbr2fl/fl or ItgaxCreTgfbr2fl/+) at postnatal day 
(P)28 and P14. Representative flow cytomety plots and graphs (±SEM) show the frequency and total 
cell numbers of AMs (Siglec-F+CD11c+, pre-gated on CD45+ cells) (A) at P14 and P28 and CD103+ 
DCs, CD11b+ DCs and interstitial MFs (IMF) (pre-gated on CD45+Ly6G-Siglec-F-Ly6C-
MHCII+CD11c+) at P14 (C). N = 4-11 from 2-3 independent experiments (A) and N = 5 from 2 
independent experiments (C). *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, unpaired). (B) 
Annotated t-SNE plots and expression of markers in the identified populations among CD45+ lung cells 
from Tgfbr2fl/fl or ItgaxCreTgfbr2fl/fl mice (P14) as in (A). Archsinh transformed medians are shown.  
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Figure 8. TGF-βR signaling is not crucial for other tissue macrophages in ItgaxCreTgfbr2fl/fl and 
Lyz2CreTgfbr2fl/fl mice. (A) Flow cytometry (left) and quantification (right) (±SEM) of kidney 
macrophages (Kidney MF), small intestinal lamina propria macrophages (SIMFs) and LCs of 
ItgaxCreTgfbr2fl/fl mice and control littermates (Tgfbr2fl/fl or ItgaxCreTgfbr2fl/+) at P28. Kidney MFs and 
SIMFs were pre-gated on CD45+Ly6G-Siglec-F-Ly6C-MHCII+CD11c+ cells. LCs were pre-gated on 
CD45+Ly6G- cells. N = 4-6, from 2-3 independent experiments. (B) Flow cytometry of lungs of adult 
Lyz2CreTgfbr2fl/fl and Tgfbr2fl/fl mice. Flow cytometry plots show the frequency of AMs (Siglec-
F+CD11c+, pre-gated on CD45+) (left) and quantification of total cell numbers (±SEM) of AMs (right). 
N = 9-11, from 3 independent experiments. (C) H&E staining of lungs from Lyz2CreTgfbr2fl/fl and 
Tgfbr2fl/fl mice.  Scale bar = 40 µm. (D) Quantification of total cell numbers (±SEM) of Ly6Chi Mo, 
Ly6Clo Mo, CD11b+ DCs, CD103+ DCs, IMFs, NPs and Eos of lungs from Lyz2CreTgfbr2fl/fl mice and 
from control littermates by flow cytometry. (Gating strategy shown in Figure S1A). N ≥ 6, from 2-3 
independent experiments. (E) Total protein concentration (left) and SP-D protein concentration (right) 
(±SEM) in the BAL from Lyz2CreTgfbr2fl/fl (either Lyz2Cre/CreTgfbr2fl/fl or Lyz2Cre/+Tgfbr2fl/fl, 6-8 weeks 
old) and from control littermates (Lyz2Cre/CreTgfbr2fl/+, Lyz2Cre/+Tgfbr2fl/+ or Tgfbr2fl/fl), N ≥ 6. *p < 
0.05; **p < 0.01; ***p < 0.001; ns, not significant (unpaired Student’s t test ). 
 
To determine the differential impact of TGF-βR signaling across the MPS, we next 
generated Lyz2CreTgfbr2fl/fl mice, in which Tgfbr2 is deleted in lysozyme-expressing 
myeloid cells including macrophages, neutrophils and monocytes. Analysis of adult 
Lyz2CreTgfbr2fl/fl mice revealed that in the lung, AMs were essentially absent, whereas 
the numbers of monocytes, DCs and interstitial macrophages were again unaltered 
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(Figure 8B-D). Also, in other non-lymphoid and lymphoid tissues, macrophages were 
present at normal frequencies in Lyz2CreTgfbr2fl/fl mice (data not shown). Concomitant 
with the absence of AMs, we found that the total protein conentration and surfactant 
protein D (SP-D) concentration increased in the bronchoalveolar lavage (BAL) of 
Lyz2CreTgfbr2fl/fl mice (Figure 8E). This is indicative of the development of PAP as 
previously shown in mice lacking AMs60,94. However, in Lyz2CreTgfbr2fl/fl mice 
(heterozygous for Cre), the numbers of AMs often recovered with age (data not 
shown). In these AMs, Tgfbr2 expression was comparable to WT levels suggesting a 
repopulation by TGF-βR-sufficient precursors and/or AMs over time. Conversely, by 
increasing the recombination frequency in Lyz2Cre/CreTgfbr2fl/fl mice (homozygous for 
Cre), AMs remained absent (data not shown) but these mice died at variable ages 
most likely due to multi-organ inflammation145,150.  
 
 
Figure 9. TGF-βR signaling is not crucial for other tissue macrophages in Vav1CreTgfbr2fl/fl mice. 
(A-B) Flow cytometry (left) and quantification (right) (±SEM) of AMs (A), kidney MFs, SIMFs, 
RPMFs and LCs (B) of Vav1CreTgfbr2fl/fl mice and control littermates (Tgfbr2fl/fl or Vav1CreTgfbr2fl/+) at 
P14. N = 3, from 2 independent experiments. (C) Relative mRNA expression levels (±SEM) of Tgfbr2 
from sorted kidney MFs and SIMFs as shown in (B), normalized to Pol2. N = 3. *p < 0.05; **p < 0.01; 
***p < 0.001; ns, not significant (unpaired Student’s t test ). 
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Lyz2Cre mice display varying degrees of recombination efficiency across the 
MPS112,151. To definitively target all members of the MPS, we analyzed 2-week-old 
Vav1CreTgfbr2fl/fl mice, in which Tgfbr2 is deleted in all hematopoietic cells152. Also 
here, while AMs and LCs were absent, other macrophage populations analyzed were 
unaffected with the exception of red pulp macrophages, which were 50% reduced 
(Figure 9A-B). Successful deletion of Tgfbr2 was verified by RT-PCR (Figure 9C). 
Taken together, TGF-βR signaling is essential for the development and/or 
maintenance of AMs but is not required for the genesis of other tissue macrophages.  
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6.2 Autocrine TGF-β is Required for AMs 
We found TGF-β to be highly expressed in the adult lung as previously shown153,154 
(Figure 10A). Within the lung, we detected its expression in epithelial cells, 
endothelial cells and AMs, with the highest expression in AMs (Figure 10B). TGF-β 
can be activated from its latent form in a cell-cell contact-dependent manner through 
the integrin avβ6 expressed by the lung epithelium155. On the other hand, it was 
shown in vitro that TGF-β can be activated by AMs in an autocrine manner by the 
interaction with thrombospondin 1, CD36 and the protease plasmin156. To evaluate 
whether TGF-β regulates AMs in an autocrine manner in vivo, we analyzed 
ItgaxCreTgfb1fl/fl mice in which Tgfb1 is deleted in CD11c+ cells. At 4 weeks of age, 
the number and frequency of AMs derived from whole lung tissue or from the BAL 
were significantly reduced in ItgaxCreTgfb1fl/fl mice (Figure 10C-D). The remaining 
cells from the BAL exhibited a foam-cell-like phenotype, characterized by enlarged 
cytoplasm and lipid accumulation as assessed with Oil Red O staining (Figure 10E). 
Collectively, these data suggest that AMs require TGF-β for their development and/or 
maintenance in an autocrine manner. 
        
 
Figure 10. TGF-β is required for AMs in an autocrine manner. (A) ELISA for TGF-β1 of the lung, 
liver, kidney and brain from WT mice, normalized to total protein amount. N = 3. (B) Relative mRNA 
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expression of Tgfb1 from sorted AMs, epithelial cells (EpC, pre-gated on CD45-Epcam+CD31-), 
endothelial cells (EnC, pre-gated on CD45-Epcam-CD31+) and other CD45- cells from WT lungs, 
normalized to Pol2. N ≥ 3. (C-D) Representative flow cytometry plots of AMs (Siglec-F+CD11c+) 
among CD45+ cells from lung tissue (C) or from bronchoalvelar lavage (BAL) (D) from 
ItgaxCreTgfb1fl/fl mice and control littermates (Tgfb1fl/fl, Tgfb1fl/+ or ItgaxCreTgfb1fl/+) and quantification 
of total cell numbers (±SEM) on the right. N ≥ 4 from 2 independent experiments. (E) Oil Red O 
staining of AMs derived from the BAL of ItgaxCreTgfb1fl/fl mice and from control littermates. Scale bar 
= 20 µm. Representative images are shown. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant 
(unpaired Student’s t test for (C-D) and one-way ANOVA for (A-B)). 
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6.3 TGF-βR Signaling is Essential for the Maintenance of Mature AMs 
To investigate the impact of TGF-βR signaling on adult AM homeostasis, we crossed 
the Tgfbr2fl/fl mice to the tamoxifen-inducible Rosa26CreER (R26CreER) mice, in which 
tamoxifen administration leads to deletion of Tgfbr2 in all cells and tissues. 6-8 week 
old R26CreERTgfbr2fl/fl mice were treated with tamoxifen every other day for 5 times 
and AMs were analyzed 7 days after the last treatment. Deletion of TGF-βR in mature 
AMs led to a significant reduction of their numbers (Figure 11A). The remaining 
AMs were found to be untargeted (Figure 11B), demonstrating that TGF-βR signaling 
on AMs is important for their maintenance. 
Again, to address whether, in addition to AMs, other tissue macrophages also depend 
on TGF-βR signaling for their homeostatic maintenance, we used 
Cx3cr1CreERTgfbr2fl/fl, in which tamoxifen administration leads to the specific deletion 
of TGF-βR in cells expressing the chemokine receptor CX3CR1+, which includes 
microglia, kidney and gut macrophages, but not AMs40. As recently demonstrated157, 
tamoxifen-inducible deletion of Tgfbr2 in adult microglia led to rapid microglia 
activation but not to their depletion. TGF-βR ablation did not alter the frequency of 
gut and kidney macrophages in Cx3cr1CreERTgfbr2fl/f mice compared to control 
littermate controls (Figure 11C-D). Successful Tgfbr2 deletion in these populations 
was confirmed by RT-PCR (Figure 11E). In contrast to microglia157, deletion of TGF-
βR in gut and kidney macrophages did not trigger their transformation into 
inflammatory macrophages in the time frame analyzed as assessed by Il1b and Tnf 
cytokine expression (Figure 11E). Together, these data indicated that the homeostasis 
of AMs required tonic TGF-βR engagement, whereas the survival of microglia, gut 
and kidney macrophages was not dependent on TGF-βR signaling. 
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Figure 11. TGF-βR signaling is required for the homeostasis of AMs. (A-B) R26CreERTgfbr2fl/fl mice 
and Tgfbr2fl/fl littermates were treated with tamoxifen (5 mg) 5 times every other day via oral gavage 
(o.g.) and analyzed 7 days after the last treatment. (A) Flow cytometry (left) of AMs (Siglec-
F+CD11c+) (pre-gated on CD45+ cells) and quantification (right) of total cell numbers (±SEM). N ≥ 9 
from 4 independent experiments. (B) qRT-PCR of Tgfbr2 mRNA from AMs (Siglec-F+CD11c+) as 
shown in (A), normalized to Pol2 expression. N = 3. (C-E) Cx3cr1CreERTgfbr2fl/fl mice and Tgfbr2fl/fl 
littermates were treated with tamoxifen every other day (max. 5 times) via o.g. and analyzed 6 and 14 
days after treatment start. Representative flow cytometry plots (left) on D6 and quantification of total 
cell numbers (right) on D6 and D14 of kidney macrophages (MF) (C) and small intestinal lamina 
propria macrophages (SI MF) (D) (pre-gated on CD45+Ly6G-Siglec-F-Ly6C-MHCII+CD11c+ cells). N 
≥ 3 from 2-8 independent experiments. (E) qRT-PCR of Tgfbr2, Il1b and Tnf mRNA from kidney MFs 
and SIMFs at D6, normalized to Pol2 expression. N = 3. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not 
significant (unpaired Student’s t test). 
 
It has been shown that activation of TGF-βR signalling in AMs might be associated 
with the adherence of these cells to lung epithelial cells158. To address whether it is 
the mechanism by which AMs require TGF-βR signalling for their maintenance, we 
have treated adult R26CreERTgfbr2fl/fl and Tgfbr2fl/fl mice with tamoxifen every other 
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day and analysed the BAL and lung tissue 6 days after the first treatment. Even 
though Tgfbr2 deletion was already evident at D6 post tamoxifen treatment, this did 
not significantly alter the number of AMs in the BAL (Figure 12A-C). Likewise, 
using immunohistochemistry, no significant difference in adherent vs. non-adherent 
AMs was detected (Figure 12D). This is indicative that the loss of AMs upon 
removing tonic TGF-βR signaling leads to cell-intrinsic AM loss. As to whether the 
dead AMs are then absorbed in situ or accumulate in the BAL cannot be formally 
demonstrated or excluded. Therefore, the data we accumulated thus far do not support 
the notion that the loss of AMs upon disruption of TGF-βR signaling is caused by the 
detachment from epithelial cells. 
 
           
Figure 12. Disruption of TGF-βR signaling is not associated with AM detachment from epithelial 
cells.  (A-D) R26CreERTgfbr2fl/fl and Tgfbr2fl/fl mice were treated with tamoxifen (5 mg) 3 times every 
other day via oral gavage and analyzed 2 days after the last treatment (D6 after treatment start). (A) 
Flow cytometry of AMs (Siglec-F+CD11c+, pre-gated on CD45+ cells) from lung tissue and BAL. 
Representative images. (B) Quantification of total cell numbers of AMs in the lung tissue (left) and the 
ratio of AMs in the BAL vs. lung tissue (right). (C) qRT-PCR of Tgfbr2 mRNA from AMs as shown in 
(A), normalized to Pol2 expression. (D) Representative image of an AM attached to lung epithelium 
(top images) and a ‘detached’ AM (bottom images) by IHC of the lung, stained for Siglec-F (green), 
DAPI (blue) and Epcam (red). Arrowheads indicate AMs. Scale bars, 20 µm. Dot plots shows the ratio 
of detached vs. total AMs. Each dot represents at least 50 AMs of ≥ 2 mice. (A-B), N = 5.  ±SEM. ns, 
not significant (unpaired Student’s t test). (C) N = 3. ±SEM. *p < 0.05, **p < 0.01(unpaired Student’s t 
test). 
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6.4 The Development of Monocyte-Derived ‘AMs’ after Irradiation Requires 
TGF-βR Signaling 
AMs self-maintain in the steady state independently of circulating precursors 
(Hashimoto et al., 2013). However, in inflammation or after lethal whole body 
irradiation and subsequent BM transplantation, BM-derived monocytes repopulate the 
AM niche58. To investigate whether in BM transplantation, those BM-derived ‘AMs’ 
are also dependent on TGF-βR signaling, BM chimeric mice were generated with a 
1:1 mix of WT (CD45.1) and Lyz2CreTgfbr2fl/fl (CD45.2) BM. Csf2rb-/- (CD45.2) or 
WT (CD45.2) BM served as controls. This setup allowed for the investigation of the 
intrinsic requirements for TGF-βR signaling for the development of BM-derived 
‘AMs’ with a competing internal WT control population. We found all AMs to be of 
WT origin whereas blood monocytes were reconstituted at a 1:1 ratio in 
Lyz2CreTgfbr2fl/fl : WT chimeras (Figure 13). This finding is reminiscent of what is 
observed when GM-CSFR signaling is disturbed58,90,94 (Figure 13) These results 
demonstrate that TGF-βR is not only important for embryonically-derived AMs but 
also for the repopulation of AMs from adult BM after total body irradiation.  
 
Figure 13. BM-derived ‘AMs’ are dependent on TGF-βR signaling. (A) Representative flow 
cytometry plots depict the frequency of CD45.1+ and CD45.2+ blood Ly6Chi monocytes (pre-gated on 
F4/80+CD115+CD11b+Ly6ChiLy6G− cells) and AMs (pre-gated on Siglec-F+CD11c+ cells) in mixed 
WT(CD45.1+) : Lyz2CreTgfbr2fl/fl (CD45.2+), WT(CD45.1+) : Tgfbr2fl/fl(CD45.2+) and WT(CD45.1+) : 
Csf2rb-/-(CD45.2+) BM chimeras. Remaining host cells (CD45.1+CD45.2+) were gated out. (B) 
Quantification (±SEM) of (A) normalized to the ratio of CD45.1+ and CD45.2+ blood Ly6Chi Mo. N = 
3-6, from 2-3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant 
(unpaired Student’s t test). 
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6.5 Embryonic Development of AMs Depends on TGF-β  
In order to define whether TGF-β signaling is a prerequisite for the embryonic 
development of AMs, we first analyzed the expression of Tgfb1 and its receptor in 
preAMs and fetal monocytes. We found the expression of Tgfb1 in fetal monocytes 
and preAMs was comparable to mature AMs, whereas Tgfbr2 and Tgfbr1 were more 
highly expressed in adult AMs compared to preAMs and fetal lung monocytes (Figure 
14).  
 
Figure 14. TGF-βRs and ligand expression in AMs and precursors (A) Relative mRNA expression 
levels (±SEM) of Tgfb1, Tgfbr2 and Tgfbr1 of sorted fetal liver monocytes (Liv Mo) at E15.5, fetal 
lung monocytes (Lg Mo), preAMs and Liv Mos at E18.5, and adult AMs and BM monocytes (BM 
Mo). N = 3. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (one-way anova). 
Next, we analyzed Lyz2CreTgfbr2fl/fl (homozygous for Cre) embryos at E18.5. Fetal 
monocytes in the developing lung were unaffected in Lyz2CreTgfbr2fl/fl mice compared 
to control littermates (Figure 15A and Figure 16A). However, a drastic decrease in 
preAMs (Ly6CloCD64hi) was noted. Within this remaining preAM population, a 
second CD11bhi population emerged in the Lyz2CreTgfbr2fl/fl lungs (Figure 15A). This 
atypical CD11bhi population arose as a result of the loss of Tgfbr2 signaling as 
verified by RT-PCR (Figure 15B). In contrast, the CD11blo preAM population 
observed in Lyz2CreTgfbr2fl/fl mice, which resembles normal preAMs, were not 
targeted and had an undisrupted Tgfbr2 locus (Figure 15B). For complete targeting of 
all hematopoietic cells in the embryo, we again used the Vav1CreTgfbr2fl/fl mice, in 
which we found AM development completely abolished at E18.5 (Figure 15C). 
Tgfbr2 deletion on fetal liver monocytes, which was confirmed by RT-PCR, did 
however not hamper their differentiation into tissue macrophages other than the lung 
(such as liver, spleen, kidney, gut and dermis) (Figure 16A-B). In other words, TGF-
βR signaling does not affect fetal liver monocyte development nor their ability to 
become tissue macrophages per se, but is highly specific to the normal developmental 
transition of fetal monocytes into AMs. 
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Figure 15. TGF-βR signaling is indispensable for the development of AMs during embryogenesis. 
(A) Representative flow cytometry plots (left) and quantification of total cell numbers (±SEM) (right) 
of fetal monocytes (fetal Mo, Ly6ChiCD11bhi) and preAMs in Lyz2CreTgfbr2fl/fl and Lyz2CreTgfbr2fl/+ 
(homozygous for Lyz2Cre) embryos at E18.5 (pre-gated on CD45+Ly6G-MHCII-F4/80loCD11b+CD64+ 
cells). N = 13, 4 independent experiments. (B) Relative mRNA expression (±SEM) of Tgfbr2 from 
sorted fetal monocytes and preAMs as shown in (A) normalized to Pol2. N ≥ 3, each from 2-4 pooled 
mice. (C) Flow cytometry analysis of fetal lung of Vav1CreTgfbr2fl/fl and Tgfbr2fl/fl mice at E18.5. Total 
cell numbers (±SEM) are quantified on the right. N ≥ 5, from 2-3 independent experiments. (D) Fold 
change of relative mRNA expression of Tgfbr2, Pparg, Csf2rb, Tgfb1 and Car4 from E15.5 fetal liver 
monocytes cultured in vitro with TGF-β1 or with anti-TGF-β1 blocking antibodies, normalized to Pol2. 
N = 3 from 3 independent experiments. (E) Relative mRNA expression levels of Pparg, Car4, Spi1, 
Csf2rb, Csf2ra, Tgfbr1 and Tgfb1 from sorted fetal monocytes and preAMs as described in (A-B), 
normalized to Pol2. N = 3, each from 2-4 pooled mice. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not 
significant (unpaired Student’s t test).  
 
	  45	  
 
Figure 16. TGF-β is not essential for the development of other macrophages. (A) Representative 
flow cytometry plots (left) and quantification of total cell numbers (±SEM) (right) of fetal liver 
monocytes (Mo, CD11b+Ly6hiCD64mid) and macrophages (MF, CD11b+CD64hi), blood Mo, and Mo 
and MF in kidney, gut, spleen and dermis in Vav1creTgfbr2fl/fl and Tgfbr2fl/fl embryos at E18.5 (pre-
gated on CD45+Ly6G-MHCII-Siglec-F- cells). N = 4-6 from 3 independent experiments. (B) Relative 
mRNA expression levels (±SEM) of Tgfbr2 of sorted fetal liver monocytes as in (A) normalized to 
Pol2. N ≥ 3, each from 1-2 mice. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (unpaired 
Student’s t test ). 
To investigate how TGF-β instructs AM development, we sorted fetal monocytes 
from WT embryonic livers at E15.5 and cultured them with GM-CSF in the presence 
or absence of TGF-β. As readout for AM differentiation, we analyzed the expression 
of Pparg and Car4, both AM signature genes. While GM-CSF served as a survival 
factor (data not shown), the addition of TGF-β induced the expression of Pparg and 
Car4 (Figure 15D). Expression of Csf2rb, Tgfbr2 and Tgfb1 was not affected by TGF-
β. Moreover, when we replaced GM-CSF with M-CSF to sustain the cell culture, 
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addition of TGF-β again induced Pparg expression (data not shown). This finding 
suggests that TGF-β stimulation in vitro induces gene expression in fetal monocytes 
that allow AM differentiation (Pparg) or are related to AM identity (Car4).  
Conversely, we also analyzed the expression of these genes in vivo in Tgfbr2-deficient 
preAMs (CD11bhi) in Lyz2CreTgfbr2fl/fl embryos. We found that Pparg and Car4 were 
weakly expressed in Tgfbr2-deficient preAMs in contrast to control preAMs (Figure 
15E). The expression of the pioneer transcription factor for the myeloid lineage PU.1 
(encoded by Spi1) was not affected by the disruption of TGF-βR signaling. On the 
other hand, expression of Tgfbr1 was reduced in Tgfbr2-/- preAMs while Tgfb1 was 
not affected. We next analyzed whether TGF-βR signaling regulates GM-CSFR. We 
found that the expression of Csf2ra and Csf2rb was unaltered upon deletion of TGF-
βR in preAMs (Figure 15E). Equally, analysis of fetal lung monocytes from Csf2rb-/- 
embryos, in which their differentiation into preAMs is disrupted, revealed that 
expression levels of Tgfbr2, Tgfbr1 and Tgfb1 were also unchanged (Figure 17A). 
Taken together, TGF-βR signaling does not impact on GM-CSFR expression in 
preAMs, or vice versa, but both pathways instruct the expression of Pparg, which is 
critical for AM differentiation. 
 
Figure 17. GM-CSFR signaling has no impact on TGF-βRs and ligand expression in preAMs (A) 
Relative mRNA expression of Tgfbr2, Tgfbr1 and Tgfb1 from fetal liver monocytes of Csf2rb-/- and 
WT mice and preAMs of WT mice at E17.5. N = 2-3, each from 2 mice. *p < 0.05; **p < 0.01; ***p < 
0.001; ns, not significant (unpaired Student’s t test ). 
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6.6 TGF-β Instructs AM Differentiation and Signature Gene Expression 
CD11c expression on AMs commences within the first 3 days postnatally. We 
observed that ItgaxCreTgfbr2fl/fl mice at P3 showed reduced, yet detectable numbers of 
AMs while at P7, AMs were already absent indicating that TGF-βR signaling is also 
critical for the maturation of AMs after birth (Figure 18A and data not shown). Thus, 
to analyze the impact of TGF-β on the entire transcriptome of AMs, we performed 
RNA-sequencing (RNA-seq) on AMs deficient of Tgfbr2 in Tgfbr2fl/fl mice at P3 but 
still present at cell numbers that allowed sorting. Reduced expression of 
approximately 60% of Tgfbr2 (exon 4) was observed in ItgaxCreTgfbr2fl/fl AMs (Figure 
9B). This incomplete deletion reflects the variable differentiation stages of AMs as 
not all have undergone genetic recombination at this time point. Nevertheless, we 
found that of a total of 10,825 expressed genes, 543 genes were differently expressed 
(P < 0.001) (Figure 18C). To verify a specific targeting of the TGF-βR pathway, we 
analyzed expression of genes previously described to be associated with TGF-βR 
signaling (Figure 18D-E)159,160. For example, TGF-β-induced genes, Hpgd, Serpine1 
and Gcnt2 were down-regulated in Tgfbr2-deficient AMs161–164. Also, genes involved 
in latent TGF-β activation such as Thbs1 and Itgb5 were expressed at low levels 
compared to control AMs158,165. Negative regulators of the TGF-β signaling pathway 
such as Smurf2, Ski and Skil, whose expression positively correlates with TGF-β 
stimulation, were lower expressed in Tgfbr2-/- AMs166,167. 
Furthermore, we also found several AM signature genes to be down-regulated in 
Tgfbr2-deficient AMs53. Among those were for example Scgb1a1, Epcam and 
Cyp4f18 (Figure 18F), some of which were among the top down-regulated genes 
(Figure 18G). Genes highly expressed in monocytes but not in mature macrophages 
were up-regulated in Tgfbr2-deficient AMs53. For example, Ndrg1 and Irf7, which are 
both implicated in the development of macrophages in vitro168,169. Conversely, 
Adamdec1, induced in macrophages upon their differentiation from monocytes170, was 
lower expressed in Tgfbr2-deficient AMs.  
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Figure 18. Gene expression profiles of Tgfbr2-deficient AMs. (A) Flow cytometry plots show the 
percentage of AMs (Siglec-F+CD11c+), pre-gated on CD45+ cells) of ItgaxCreTgfbr2fl/fl mice and control 
littermates (Tgfbr2fl/fl or ItgaxCreTgfbr2fl/+) at P3. (B-H) AMs were sorted from ItgaxCreTgfbr2fl/fl mice 
and control littermates at P3 as in (A) for NGS. (See also gating strategy for NGS in Figure S1C). N = 
4, each from 2-4 mice. (B) Normalized expression counts of Exon 4 of Tgfbr2. (C) Heat map of 
expression values of genes expressed differentially in ItgaxCreTgfbr2fl/fl or Tgfbr2fl/fl AMs. (Significant p 
value < 0.001, FDR = 0.020). (D) Heat map showing differentially expressed genes belonging to the 
TGF-βR signaling pathway (GO:0007179, log10P = -5.25, fold change (FC)). (E) GSEA of genes 
expressed differentially in ItgaxCreTgfbr2fl/fl compared to Tgfbr2fl/fl AMs. Enrichment plot for ‘TGF-β 
signaling’. (P = 0.0045, FDR= 0.034). (F) Differentially expressed AM and monocyte signature 
genes53 in ItgaxCreTgfbr2fl/fl and Tgfbr2fl/fl AMs (log2 (FC) > 0.5) (G) Fold change in expression of the 
25 most significantly up- or down-regulated genes in AMs from ItgaxCreTgfbr2fl/fl mice compared to 
Tgfbr2fl/fl mice. (H) Normalized expression counts of Pparg. Runx1, Csf1r, Csf2rb and Spi1. *p < 0.05; 
**p < 0.01; ***p < 0.001; ns, not significant (unpaired Student’s t test).  
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Lipid metabolism in AMs is critical for surfactant catabolism. Consistent with the 
mRNA expression data of preAMs (Figure 15E), in the absence of Tgfbr2 we 
observed a reduction in Pparg, the master transcription factor involved in lipid 
metabolism171 (Figure 18H). Other genes such as Apoe, mediating cholesterol efflux 
and preventing foam cell formation, and Olr1, a scavenger receptor mediating oxLDL 
update, were also down-regulated in AMs lacking Tgfbr294,172 (Figure 18F, H). 
Furthermore, the expression of Csf1r and Csf2rb were both reduced upon deletion of 
Tgfbr2 in AMs. Runx1, a transcription factor highly expressed in hematopoietic 
progenitor cells173,174, was also decreased in the absence of Tgfbr2. On the other hand, 
Spi1 was not affected (Figure 18H). Overall, these data suggest that TGF-βR 
signaling leads to transcriptional changes in AM differentiation, maturation and 
signature. 
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6.7 PPAR-γ Agonist can not Rescue Tgfbr2-deficiency Induced AM Loss 
 
          
Figure 19. Rosiglitazone could not rescue AM loss in Tgfbr2-deficient mice. (A) Neonatal 
ItgaxCreTgfbr2fl/fl, Tgfbr2fl/fl and Csf2rb-/- mice (P2-P4) were treated with 10 µg Rosiglitazone in 10% 
DMSO or 10% DMSO every day for 12 days i.n. and analyzed one day after the last treatment (A-C). 
(A) Flow cytometry of AMs (CD11c+, pre-gated on CD45+Ly6C-Ly6G- F4/80+CD64+ SiglecF+ live 
cells) from the lung (left) and quantification of total cell numbers of AMs (right). (B) Flow cytometry 
analysis of FABP4 expression by AMs as shown in (A) from Tgfbr2fl/fl mice treated with DMSO or 
Rosiglitazone. N = 3, one representative histogram is shown. (C) qRT-PCR of Cd36 mRNA from AMs 
sorted from Tgfbr2fl/fl mice either treated with DMSO or Rosiglitazone, normalized to Pol2 expression, 
N = 3. ±SEM is shown. *p < 0.05, ns, not significant (unpaired Student’s t test). 
Previously, we have concluded that Pparg is regulated by TGF-βR signaling in both 
preAMs and AMs. Whether TGF-βR deficiency mediated PPAR-γ loss fully explains 
the phenotype of AMs we observed is not clear. To address this question, we treated 
ItgaxCreTgfbr2fl/fl neonates with PPAR-γ agonist rosiglitazone intranasally (i.n.) for 12 
days. This did not however significantly influence total AM numbers (Figure 19A). 
Functionality of the compound was confirmed by the anticipated upregulation of 
PPAR-γ targets175,176 CD36 and FABP4 on WT AMs (Figure 19B-C). Moreover and 
importantly, the link between GM-CSF and PPAR-γ is widely held as solid. However, 
treating Csf2-/- 60 or Csf2rb-/- mice (Figure 19A) with rosiglitazone also failed to 
restore AM numbers. Thus, these data illustrate that administration of rosiglitazone is 
insufficient to overcome the loss of AMs driven by ablation of Tgfbr2. Taken 
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together, independent of the pathway controlling Pparg (Tgfbr2 or Csf2rb), loss of 
Pparg and AMs cannot be restored with rosiglitazone, indicating that more profound 
changes than merely PPAR-γ loss induced transcription disruption in AMs occur upon 
Tgfbr2 or Csf2rb deletion.  
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6.8 Flu-induced AM Loss is not Associated with the Reduced Expression of 
Pulmonary TGF-β and TGF-βRs. 
 
                  
Figure 20. The expression of TGF-βRs and ligand post influenza virus infection. (A-C) WT mice 
were administrated with either 5000 PFU influenza virus (PR8) or PBS i.n. and analyzed at D4 or D7 
post infection. (A) The number of AMs (Siglec-F+CD11c+, pre-gated on CD45+ cells) at D4 and D7 
was quantified by flow cytometry analysis. (B) qRT-PCR of Tgfb1, Tgfbr1 and Tgfbr2 mRNA from 
sorted AMs or total lung tissue at D4, normalized to Pol2 expression. (C) Elisa of total TGF-β1 from 
lung tissue or from BAL at D4 and D7. N = 5. ±SEM, *p < 0.05, **p < 0.01, ***p < 0.001; ns, not 
significant (unpaired Student’s t test). 
The macrophage disappearance reaction is a common observation in the lung 
immunology field177,178. To address whether inflammation induced loss of AMs 
relates to TGF-βR signaling, WT mice were infected i.n. with influenza virus PR8, 
which expectedly leads to a decrease of AMs as previously described58 (Figure 20A). 
However, influenza virus infection did not significantly alter Tgfb1 expression in 
AMs (Figure 20B). Thus, autocrine TGF-β signaling is still intact, which does not 
support reduced TGF-β signaling as a mechanism of AM reduction. Also, at a later 
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point in time, when AMs are already reduced, we found a significant increase of 
TGF-β in the BAL but not in the lung tissue (Figure 20C). This increase in TGF-β is 
indicative of a response to inflammation as this commonly occurs across multiple 
inflammatory conditions. Taken together, it indicates that lack of TGF-β and its 
receptors is not the reason for the loss of AM in during influenza infection. 
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7 Discussion  
7.1 TGF-β is Essential for the Differentiation and Homeostasis of AMs. 
The development and maintenance of most macrophages is dependent on CSF-1R 
signaling. AMs, on the other hand, are much less affected by the absence of CSF-1R 
signaling than other tissue resident macrophages. This correlates with its low CSF-1R 
expression levels compared to other tissue macrophage populations53. Conversely, 
AMs, like LCs and microglia, express high levels of TGF-βRs in the steady state. 
Here we utilized different Cre/LoxP mouse lines with Tgfbr2-specific deletion to 
study the role of TGF-βR signaling in the development and maintenance of AMs and 
other macrophage populations. 
In ItgaxCreTgfbr2fl/fl, Lyz2CreTgfbr2fl/fl, and Vav1CreTgfbr2fl/fl mice where AMs lack 
TGF-βR2 expression, the lungs are devoid of AMs. Although associated with various 
degree of tissue inflammation as described previously145,150, other myeloid cell 
populations that are targeted in these mice, for example pulmonary DCs in 
ItgaxCreTgfbr2fl/fl mice and macrophages from kidney and small intestines in 
Vav1CreTgfbr2fl/fl  mice are not significantly altered in number. Exceptions are LCs, 
known to be deficient in the absence of TGF-βR signaling, that were found to be 
depleted and red pulp macrophages that were also reduced. We demonstrated that 
AMs are unique in their complete dependency on TGF-βR signaling during 
development and high sensitivity to the lack of TGF-βR signaling. Consistent with 
this, Tamoxifen-induced depletion of TGF-βR2 in adult R26CreERTgfbr2fl/fl mice also 
led to a drastic reduction of AMs in number, indicating that TGF-βR signaling is 
constantly required by AMs for their homeostasis after birth.  
The impact on cellular events following the disruption of TGF-βR signaling in adult 
AMs has not been identified yet. This is not likely due to impaired cell division since 
the turnover rate of AMs is much slower than the speed of AM loss as we observed 
here60. Meanwhile, we did not observe altered rate in cell death in the in vitro AM 
culture (data not shown). It has been suggested by many studies that AM identity and 
function are highly dependent on its contact with lung epithelia73,97,98, leading to the 
hypothesis that loss of TGF-βR signaling affects AM adhesion with epithelial cells. In 
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RNA-sequencing experiment assessing the transcriptomic programs of Tgfbr2-
deficient AMs and WT AMs, we identified multiple genes involved in cell attachment 
and migration highly downregulated in Tgfbr2-deficient mice. Nevertheless, in 
physiological analyses using immunofluorescent imaging and flow cytometry, we 
could not identify strong changes in AM adhesion to epithelia in the absence of TGF-
βR signaling during the processes of AM loss in tomaxifen administrated 
R26CreERTgfbr2fl/fl mice. Technically, to better observe and define attached AMs and 
detached AMs with electron microscopy should help us to study the direct changes in 
cellular behaviors of AMs upon Tgfbr2-deletion. 
During embryogenesis, we further characterized that preAMs at E18.5 are present as 
CD11bloLy6loCD64+F4/80+SiglecF-CD11c- population whereas their precursors, the 
fetal monocytes, are CD11bhi Ly6Chi similarly to data from previous findings60,94. In 
mice lacking TGF-βR2 at various time points during embryogenesis, we found a 
differentiation disruption and arrest specific to preAM, but neither to other tissue 
resident macrophages nor at fetal monocyte level. This demonstrates that TGF-βR 
signaling is specifically required for the differentiation of preAM from fetal 
monocyte, whereas the survival and migration of fetal monocyte itself is not TGF-βR 
signaling dependent. Interestingly, while Vav1CreTgfbr2fl/fl mice had a complete loss of 
preAM population, a remained preAM population was found in Lyz2CreTgfbr2fl/fl mice, 
in which a second Tgfbr2-deficient CD11bhi population emerged. It can be explained 
by the insufficient and late targeting in Lyz2Cre where Lyz2Cre is only initiated at 
pulmonary fetal monocyte stage rather than fetal liver monocyte stage. This 
insufficient targeting on the other hand leaves a window for exploring the 
downstream effects after TGF-βR2 depletion during development.  
Although a wide range of cells in the lung can secrete TGF-β, here we show that an 
autocrine source of TGF-β is essential for AMs maintenance in adult. The source of 
TGF-β during embryonic AM development is still unclear and demands further 
investigations. In fact, AM itself produces more abundant TGF-β compared to 
epithelial cell, the only cell type that has direct contact with AM in the steady state. 
At the same time, integrin αvβ6 expressed by lung epithelial cells has been shown to 
play a crucial role in TGF-β activation107. Our findings add to this current model that 
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the epithelial cells offer avβ6 to activate AM derived inactive TGF-β and in turn 
sustain an active TGF-βR signaling for AMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  57	  
7.2 Regulatory Networks of AM Development 
Tissue-resident macrophages are functionally and phenotypically distinct populations 
located in different organs. The commitment to macrophage relies on pioneer 
transcription factor PU.1 and other macrophage lineage-defining factors. On top of 
that, tissue-specific transcription factors and induced epigenetic landscapes define the 
unique identity for each tissue-resident macrophage population. However, the 
understanding of how local mediators contribute to the establishment of such diverse 
gene expression patterns in different tissues is still limited. Here, in the lung, we 
identified TGF-β as a critical factor that regulates expression of genes associated with 
AM differentiation and fate. 
TGF-β was previously shown to be critical for the development of LCs and was also 
implicated in the formation of microglia93,148,179,180. Our work demonstrated that TGF-
β is also a prerequisite for the embryonic development of AMs and their maintenance 
throughout life. In LCs, TGF-βR signaling was shown to induce the expression of 
transcription factors Id2 and Runx3, both essential for LC commitment144,181. In 
microglia, TGF-β leads to the expression of the transcriptional regulator Sall1, which 
is highly expressed in microglia but not in other tissue macrophages148,157. Here we 
showed that TGF-βR signaling in fetal monocytes leads to the upregulation of PPAR-
γ, a key transcription factor for the genesis of AMs. A few studies linked TGF-β to 
PPAR-γ, however, mainly demonstrating a negative regulation. It has been shown, for 
example, that PPAR-γ antagonizes TGF-β pathway or that TGF-β signaling 
negatively modulates the transcriptional activity of Pparg182,183. Another report has 
demonstrated the phosphorylation of PPAR-γ upon TGF-βR signaling184. Here, our 
data suggest that PPAR-γ is directly induced by the TGF-βR signaling pathway. 
Alternatively, the upregulation of PPAR-γ could also be a consequence of TGF-β-
induced AM differentiation, which correlates with Pparg expression. Altogether, this 
suggests that TGF-βR signaling in macrophages is linked to macrophage ‘signature’ 
genes encoding transcription factors specific for either their development (PPAR-γ for 
AMs, Id2 and Runx3 for LCs) or their fate (Sall1 for microglia). We demonstrated 
that the development of other tissue macrophages than the aforementioned ones do 
not depend on TGF-βR signaling. 
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Among tissue resident macrophages, the genesis of AMs is also unique in its high 
dependency on GM-CSFR signaling. GM-CSFR signaling has been shown to be 
essential for the differentiation of fetal monocytes into immature AMs perinatally and 
for the full maturation of AMs postnatally but not for the accumulation of fetal 
monocytes in the developing lung60,94. Our data demonstrated that, in parallel to GM-
CSFR signaling, TGF-βR signaling also functions at the stage of preAM 
differentiation and maturation but not at fetal monocyte level. TGF-βR and GM-
CSFR signaling converge to induce the expression of PPAR-γ, a key factor for the 
transcriptional program specific to AMs94. The requirement for two individual 
cytokines for macrophage development is also reminiscent of LCs, which are 
dependent on IL-34 and TGF-β91,93. 
Despite the equal necessity for the genesis of AMs, GM-CSFR and TGF-βR pathways 
induce differential transcriptional behaviors that function complementarily in AM 
development and maintenance. GM-CSF mediated AM differentiation and 
homeostasis is largely through the pioneer transcription factor PU.1114 that functions 
at the common macrophage lineage commitment level. PU.1 expression restores the 
functionality of GM-CSFR deficient AMs and GM-CSF controls Spi1 (gene encoding 
PU.1) transcription185–187. In contrast, TGF-βR has no impact on Spi1 transcription at 
both embryonic and neonatal stages of AM development. Together, it suggests that 
TGF-β is involved in the induction of AM identity, while GM-SCF might serve as a 
counterpart of CSF-1 in the lung to maintain PU.1 expression 188.  
GM-CSF is secreted by epithelial cells and acts in a paracrine manner on AMs175, 
while AMs are dependent on autocrine TGF-β in adulthood. During development, the 
fetal lung expresses higher levels of GM-CSF than other organs including heart, 
spleen, brain, kidney and liver175, whereas TGF-β is present in both the fetal liver and 
lung at similar level (data not shown). The receptors for TGF-β are upregulated after 
fetal monocytes migrate from liver to the lung and are further increased when they 
become mature AMs after birth. It will be interesting to analyze factors that control 
TGF-βR expression during AM development. 
The crosstalk between GM-CSFR and TGF-βR signaling in AMs remains to be 
discovered. We did not observe an impact of GM-CSFR deletion directly on the 
expression level of Tgfbrs and Tgfb1 and vice versa, Tgfbr2-deficient AMs had 
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unaltered Csf2r expression at embryonic stage. At P3, Tgfbr2-deficient AMs, 
however, showed decreased Csf2r expression. At the intracellular signaling level, 
TGF-βR and GM-CSFR signaling networks overlap in many branches, such as the 
MAPK/ERK, PI3K/AKT and SRC pathways113,118. Normal activation states and the 
dynamics of these pathways might depend on both TGF-βR and GM-CSFR signaling 
that coordinately regulates downstream transcriptional events and determine cell fate. 
Lacking one of the signaling activities might alter the signaling events of the other, 
resulting in the disturbance of the entire cellular behaviors.  
As the common target of TGF-βR signaling and GM-CSFR signaling, PPAR-γ itself 
as the only master transcription factor for the genesis of AMs is under debate. It is 
only until recently when researchers characterize PPAR-γ as an AM-specific 
transcription factor that people treat the high expression of PPAR-γ as equivalent to 
the AM identity85,108,175. It is true that as a master for lipid metabolism PPAR-γ 
undertakes important and specific function for AMs175,189. Indeed, no data support that 
PPAR-γ alone could rescue the loss of tonic signaling activity either with what we 
have shown here the loss of TGF-βR2 or in literature the lack of GM-CSF60. These 
studies mainly use PPAR-γ agonists. A true restoration of Pparg mRNA should better 
reflect to what extent could PPAR-γ overcome the loss of tonic cytokines. Similarly, 
experiments with overexpression of Pparg in other tissue-resident macrophages are 
missing. In summary of current findings, AM identity should not be over simplified 
and limited to the presence of PPAR-γ. 
We could not detect Bach2 expression by preAMs at E17.5 (data not shown) nor by 
AMs at P3 based on sequencing reads, indicating that this transcription factor is not 
involved in AM genesis. For this reason, we did not continue the study of the impact 
of GM-CSFR and TGF-βR signaling on it. For future, unbiased characterization of the 
interplays between GM-CSFR and TGF-βR signaling in either in vitro stimulated AM 
or AM precursor culture or in fetal monocytes in the lung should help to identify key 
players in AM development.  
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7.3 Implications in Pulmonary Function and Diseases 
It has been shown in both human and mice that deficiency in GM-CSF or its receptors 
leads to AM loss and further cause the disease PAP. Here, in mice lacking AMs due 
to deletion of TGF-βR, SP-D and total protein concentrations in the BAL were also 
found increased, indicating the onset of PAP. These results demonstrate that the 
development of PAP resulted not only from Csf2 or Csf2rb deficiency, but also from 
the loss of tonic TGF-β, thereby supporting the importance of both pathways in 
forming and maintaining AMs. Of note, histomorphological changes manifest only in 
aged mice. This could so far not be addressed with the mice used here since strains 
lacking AMs succumb to multi-organ inflammation before they would develop PAP 
or conversely, AMs that escaped gene-targeting repopulated the empty niche. 
Altogether, our finding suggests that functional AMs are the key component in 
maintaining lung respiratory function. PAP is a direct consequence of AM loss, rather 
than solely based on one cytokine GM-CSF. In clinic, the contribution of TGF-βR 
signaling disruption to the AM loss and to the PAP development is worth further 
investigation. 
Inflammation leads to cytoablation of tissue-resident macrophages with simultaneous 
increased monocytes, moDCs or monocyte derived macrophages58. Whether it 
correlates with the loss of TGF-β is not known. We did not observe altered Tgfb1, 
Tgfbr1 or Tgfbr2 expression in AMs nor in the entire lung tissue in influenza virus 
(PR8)-infected WT mice, indicating that inflammation-induced macrophage loss is 
not a consequence of altered TGF-βR signaling. Nevertheless, the impact of infection 
on TGF-β extracellular activation and the actual signaling events after infection has 
not been studied here. In different infection and allergy models and at different time 
during the disease progression, the role of TGF-βR signaling and its impact on AMs 
and MdCs is complex and requires further study. 
Our study focused on the steady state AMs and revealed that TGF-β is one of the 
factors that shape the proper developmental pathway and maintain the homeostatic 
function of AMs. By understanding the regulatory pathways in AM development, 
researchers could regenerate not only alveoli but healthy AMs in regenerative 
medicine and for transplantation purpose190,191. Study of the homeostatic niche leads 
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to the open questions: what are the mediators that determine AM functions in an 
inflammatory or diseased setting and how would monocyte-derived macrophages 
respond differently from the resident AMs? Understanding the inflamed and disease-
related niche and comparing it to the required niche in the healthy tissue, we would 
find the answers to these questions and have efficient strategies to combat chronic 
diseases. 
In line with this, our findings of TGF-β as an indispensible factor for homeostatic 
AMs add to the current knowledge of TGF-βR signaling in lung pathology. When 
choosing TGF-βR signaling as a therapeutic target for inflammation induced fibrosis 
and tissue remodeling of the lung, attention must be paid towards the influence of 
TGF-β on resident AMs. Traditionally, TGF-β is recognized as the major responsible 
factor for fibrosis and tissue remodeling in the chronic inflamed lung, for example in 
COPD and asthma patients and counteracting against TGF-βR signaling becomes an 
interesting therapeutic target. Recently, many studies suggest that mature AMs are the 
‘good’ macrophages via suppressing inflammation, while MdCs are the ones 
exacerbating symptoms103. Thus, a potential protective role of TGF-βR should not be 
neglected in designing clinical treatment. In allergic asthma, pro-inflammatory 
macrophages expand and dominate in the BAL and after repeated allergen challenge, 
IL-4, IL-13, and IFN-γ direct or indirectly change macrophage functions103.  How to 
reset the function of those macrophages is based on the homeostatic requirements of 
AM. Since we showed that TGF-βR signaling is indispensible for AMs in their self-
maintenance, TGF-β could play a positive role in curing chronic lung disorder.  
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8 Conclusion  
Whereas it is now firmly established that almost all tissue macrophages arise from an 
embryonic precursor and are self-maintained, the regulatory mechanism for their 
tissue-specific differentiation remains largely unknown. Current knowledge of 
mediators in AM development is limited to the cytokine GM-CSF and the AM-
specific transcription factor PPAR-γ. Here we identified TGF-β as another crucial 
differentiation factor to control the formation of AMs in the developing lung and to 
maintain AM identity in an autocrine manner in the adult. The effect of TGF-βR 
signaling on AM development is specific, as the genesis of other macrophages does 
not require TGF-β receptor signaling. In parallel to GM-CSF, TGF-β regulates 
expression of proteins, including PPAR-γ, that is associated with AM differentiation 
and fate decision.  
Taken together, we demonstrated that TGF-βR signaling promotes genesis, 
maturation and survival of AMs. These findings reveal an additional layer of 
complexity regarding the guidance cues, which govern the formation and diversity of 
tissue-resident macrophages. It contributes to defining healthy tissue 
microenvironment, based on which a better understanding of pulmonary disorders can 
be achieved in the future. 
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9 Methods 
9.1 Experimental Animals.  
C57BL/6 and C57BL/6-CD45.1 mice were purchased from Janvier Labs. ItgaxCre, 
Lyz2Cre, Vav1Cre, R26CreER, Cx3cr1CreER, Tgfbr2fl/fl, Tgfb1fl/fl and Csf2rb-/- 
(Csf2rbLacZ/LacZ) were bred in-house40,112,152,192–196. 
Mice were bred and maintained in groups of 1-5 animals per cage in the specific 
pathogen-free facility of Laboratory Animal Services Center (LASC), University of 
Zurich. Unless otherwise stated, 6-12 week old littermates of both sexes were used. 
All animal experiments performed in this study were approved by the Swiss 
Veterinary Office. 
9.2 Method Details  
9.2.1 Genotyping 
Biopsies (ear clips, toe tips or tail) were lysed for 1 h at 95°C in 200 µl 50mM NaOH. 
30 µl 1M Tris-HCl pH 8.5 was added to neutralize the reaction. Samples were 
centrifuged at 12’000 rpm to pellet the tissue debris and the supernatant was used for 
DNA analysis. 
For genotyping 1 µl of DNA template and 0.5 µl of each primer (10 µM, Thermo 
Fisher Scientific) was used in 1x Hot Fire Pol Blend master mix (Solis BioDyne). 
PCR reaction was performed on C1000 Thermal Cycler (BioRad) and PCR products 
were analyzed in a 1.5-2.0 % Agarose (Biocompare) gel containing GelRed 
(Biotium). The primers used are listed in below: 	  	  	  	  	  	  	  	  
	  64	  
Mouse 
strain Primer Primer sequence 
Ann. 
temp 
Amplicons 
(bp) 
Lyz2Cre 
1 CTT GGG CTG CCA GAA TTT CTC 
62°C 
wt: 350 
mut: 700 
 
2 TTA CAG TCG GCC AGG CTG AC 
3 GCATTGCTGTCACTTGGTCG 
Tgfb1fl 
1 AAG ACC TGG GTT GGA AGTG 
60°C 
 
wt: 216 
mut: 277 
 
2 CCC AGA AAT GCC AGA TTA CG 
General cre 
1 TCCAATTTACTGACCGTACAC 
52°C wt: none mut: 700 2 CATCAGCTACACCAGAGACGGAAATC  
Vav1Cre 
1 CTA GGC CAC AGA ATT GAA AGA TCT 
64°C wt: 324 mut: 236 
2 CCCAAAGACCCACTCATTTGCAGC 
3 TTGTCAAGACCGACCTGTCCG 
4 GACGAGATCATCGCCGTCGGGCA 
Tgfbr2fl 
1 TAT GGA CTG GCT GCT TTT GTA TTC 
58°C wt: 422 mut: 575 2 TGG GGA TAG AGG TAG AAA GAC ATA 
 
9.2.2 Bone Marrow Chimeras.  
BM cells were flushed out from the bones (femur, tibia, humerus and hip). Cells were 
filtered through a 70 µm cell strainer, washed with PBS and red blood cells were 
lysed with lysis buffer (4.15 g NH4Cl, 0.55 g KHCO3, 0.185 g EDTA in 500ml 
ddH20). Mice were lethally irradiated (split dose, 2 x 550 Rad with a 24h interval) 
and were injected i.v. with at least 5 × 106 BM cells. Reconstituted mice were 
analyzed 6-10 weeks after the BM transplant. 
9.2.3 Tamoxifen Treatment.  
Tamoxifen (Sigma) was dissolved in corn oil at 25 mg/ml. 5 mg (200 µl) were 
administered via oral gavage (o.g). 
9.2.4 Influenza Virus Infection 
WT mice were anesthetized using isoflurane and administrated with either 5000 PFU 
influenza virus (PR8) in 30 µl PBS or 30 µl PBS alone i.n. and analyzed at D4 or D7 
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post infection. The body weight of mice was monitored every day post infection and a 
maximal of 10% weight loss was allowed during the whole experiment process. 
9.2.5 Rosiglitazone Administration 
Neonatal mice (P2-P4) were anesthetized using isoflurane and treated with 10 µg 
Rosiglitazone in 10% DMSO or 10% DMSO alone every day for 12 days i.n. and 
analyzed one day after the last treatment. 
9.2.6 Cell Suspension Preparations.  
Cell suspensions were prepared as previously described (Bogunovic et al., 2009; 
Greter et al., 2012a; Greter et al., 2012b). Briefly, Mice were sacrificed by CO2 
inhalation and intracardially perfused with approximately 20 ml PBS. Ear (for dermis 
and epidermis), lung, spleen, kidney, small intestine and liver were carefully 
removed. Small intestine were first cleared off feces, cut open longitudinally, washed 
with HBSS (without Ca2+/Mg2+), plus 1.35mM EDTA and 2% FBS 3 times and 
incubated with HBSS (without Ca2+/Mg2+), plus 1.35mM EDTA, 2% FBS and 1mM 
DTT for 12 min. Lung, spleen, kidney, small intestine (cleaned) and liver were cut 
into small pieces, followed by a digestion in 0.4 mg/ml collagenase type IV (from 
Clostridium histolyticum) in HBSS (with Ca2+/Mg2+) supplemented with 10 % FCS 
for 45 min at 37 °C. Epidermis and dermis were separated after Dispase digestion (1.2 
mg/ml in HBSS) for 1.5 h, cut into small pieces, incubated in 0.4 mg/ml collagenase 
type IV (Sigma-Aldrich) in HBSS with 10% FBS for 2 h. Digested tissues were 
passed through an 18 G syringe and filtered through a 70 µm cell strainer to obtain a 
homogeneous cell suspension. Liver cell suspensions were further enriched by a 30% 
Percoll gradient as previously described91,109 and centrifuged at 1700 rpm for 30 min. 
After washing in PBS, red blood cells were lysed in 1 ml lysis buffer (4.15 g NH4Cl, 
0.55 g KHCO3, 0.185 g EDTA in 500ml ddH20) and stained. 
9.2.7 Flow Cytometry  
Cell pellets were resuspended in the antibody mix in PBS and stained at 4 C° for 25 
min. After washing with PBS, cell pellets were resuspended in FACS buffer (2 mM 
EDTA, 2% FCS in PBS) and analyzed. Flow cytometry was performed using an 
LSRII Fortessa (Becton Dickinson/BD Biosciences) and analyzed with FlowJo 
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software (Tree Star). Cell sorting was carried out using a FACSAria III. 
Fluorochrome-conjugated monoclonal antibodies (mAbs) specific for mouse I-A/I-E 
(clone M5/114.15.2), CD11b (clone M1/70), CD11c (clone N418), CD45 (clone 30-
F11), CD45.1 (clone A20), CD45.2 (clone 104), CD115 (clone AFS98), Ly6C (clone 
AL-21 or HK1.4), Ly6G (clone 1A8), Siglec-F (clone E50-2440), CD3 (clone 17A2), 
CD45R (clone RA3-6B2), CD64 (clone X54-5/7.1), CD103 (clone 2E7), CD24 (clone 
M1/69), CD31 (clone 390), EpCam (clone G8.8) purchased either from BD 
Biosciences, eBioscience, or Biolegend. Anti-F4/80 (clone Cl:A3-1) mAb was 
purchased from AbD. Anti-mouse CD16/32 (Biolegend) was included in all the 
staining panel. Prior to detailed analysis cells were always gated on single, live cells, 
dead cells were excluded with the Fixable Viability Kit (Aqua or Near-IR staining, 
Biolegend).  
9.2.8 t-SNE Display.  
FCS files of single, live CD45+ cells (30,000 cells per sample) were exported from 
FlowJo X (Tree star) and uploaded to Cytobank (http://fluidigm.cytobank.org) for t-
SNE visualization based on all surface markers in the staining panel, excluding CD45 
and live/dead markers. Different key populations were gated manually based on t-
SNE separation and overlayed back onto the t-SNE map. Subsequently, the marker 
expression levels for each population were extracted from Cytobank and visualized in 
R as a heatmap. 
9.2.9 Bronchoalveolar Lavage  
Bronchoalveolar lavage (BAL) was performed by flushing the lungs twice with 400 
µl 0.5 mM EDTA/PBS using 22 G x 1.00 Insyte-W™ peripheral venous catheter 
(BD).   
9.2.10 Oil Red O Staining 
Cells derived from the BAL were spun onto slides precoated with 0.01% poly-L-
lysine. After fixing for 10 min with 4% PFA, cells were washed with PBS and rinsed 
with 60% isopropanol, stained for 20 min with 0.3% Oil Red O (Sigma) in 60% 
isopropanol, followed by 2 min of destaining in 60% isopropanol and washing with 
PBS. Subsequently, cell nuclei were stained with hematoxylin for 2 min and rinsed 
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with tap water. Sections were mounted with immunoselect antifading mounting 
medium (Dianova).  
9.2.11 H&E staining of Lung Tissue Sections 
The lungs were perfused with PBS, removed, fixed in HOPEI for 72 hours, incubated 
in HOPEII/acetone for 2 hours, and followed by pure acetone incubation for 6 hours 
and paraffin incubation overnight. Lungs were embedded in paraffin and 5 µm 
sections were cut for H&E stainings. Briefly, sections were deparaffinized in Xylene 
for 5 min 3 times and rehydrated in 100% ethanol twice, 95% ethanol twice and 70% 
ethanol each for 3 min. After being rinsed with distilled water for 5 min, sections 
were stained in hematoxylin for 5 min, rinsed in running tap water for 1 min, and 
counterstained with Eosin for 1 min. Dehydration was done in serial rinsing twice in 
95% ethanol and twice in 100% ethanol. After being cleared with Xylene for 3 min, 
sections were mounted in DPX mounting medium.  
9.2.12 Immunofluorescence Staining of Lung Tissue Sections  
Mice were euthanized with barbiturate and perfused with PBS. Lung was removed 
and fixed in 4% paraformaldehyde (Kantonsaptheke, Morphisto) for 48 h, followed 
by incubation in 30% sucrose (Sigma)/PBS solution for 24 - 48 h prior to embedding 
in OCT Cryo embedding medium (Medite) on dry ice. Cryo-sections were stored at -
80°C. For immunohistochemistry, 20 µm sections were cut and washed once with 
PBS to remove OCT medium. Sections were blocked for 1 h at RT with 10% normal 
goat serum (NGS, Thermo Fisher Scientific) /0.5% Triton-x100 (Sigma)/PBS 
solution. Primary antibodies were diluted in 4% NGS /0.1% Triton-x100/PBS 
solution and incubated for 2 h at RT or overnight at 4°C. After washing with PBS, 
sections were incubated with secondary antibodies against the host IgG (Invitrogen) 
for 0.5-1 h at RT. Sections were washed again and covered with DAPI containing 
immunoselect antifading mounting medium (Dianova).  
9.2.13 In vitro Culture of Fetal Monocytes 
Fetal monocytes (CD45+Ly6G-Ly6C+CD11b+CD64int) were sorted from fetal livers 
(E15.5) and cultured at 50,000 cells per well in 48-well plates in complete DMEM 
medium (PAN Biotech), plus 1 mM Sodium Pyruvate, 1x GlutaMAX (Gibco), 10% 
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FCS, 1% Pen/Strep (Gibco), 50 µM β-Mercaptoethanol (Gibco), 10 mM HEPES 
(Gibco) with 50 ng/ml GM-CSF (Biolegend). Cells were co-cultured with either 8.6 
µg/ml mouse IgG1 isotype control (MOPC-21, BioXcell), 8.6 µg/ml anti-pan TGF-β1 
antibody (clone: 1D11.16.8, BioXcell), or with 10 ng/ml hTGF-β1 (PeproTech) and 
8.6 µg/ml mouse IgG1 isotype control for 24h. Cells were then processed for RNA 
isolation. 
9.2.14 Quantitative RT-PCR (qRT-PCR).  
Total RNA was isolated using RNeasy micro plus kit (Qiagen). cDNA was 
synthesized with M-MLV reverse transcriptase (Invitrogen) and qRT-PCR was 
performed on a C1000 Touch Thermo Cycler (Bio-Rad) using SYBR Green (Bio-
Rad). Primers used are listed here: 
Tgfbr2 forward: AAC GAC TTG ACC TGT TGC CTG T 
Tgfbr2 reverse: CTT CCG GGG CCA TGT ATC TT 
Tgfb1 forward: TGA CGT CAC TGG AGT TGT ACG G 
Tgfb1 reverse: GGT TCA TGT CAT GGA TGG TG 
Tgfbr1 forward: CAT TCA CCA CCG TGT GCC AAA TGA 
Tgfbr1 reverse: ACC TGA TCC AGA CCC TGA TGT TGT 
Pol2 forward: CTG GTC CTT CGA ATC CGC ATC  
Pol2 reverse: GCT CGA TAC CCT GCA GGG TCA 
Csf2ra forward: CTG CTC TTC TCC ACG CTA CTG 
Csf2ra reverse: GAG ACT CGC CGG TGT ATC C 
Csf2rb forward: GTG GAG CGA AGA GTA CAC TTG 
Csf2rb reverse: CC AAA GCG AAG GAT CAG GAG 
Pparg forward: GTG ATG GAA GAC CAC TCG CAT T 
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Pparg reverse: CCA TGA GGG AGT TAG AAG GTT C 
Car4 forward: CTC CTT CTT GCT CTG CTG 
Car4 reverse: GAC TGC TGA TTC TCC TTA 
Spi1 forward: GAT GCA CGT CCT CGA TAC TC 
Spi1 reverse: TCA TCT GAG CTC TGC TG GTG 
Il1b forward: GAT CCA CAC TCT CCA GCT GCA 
Il1b reverse: CAA CCA ACA AGT GAT ATT CTC CAT G 
Tnf forward: CAT CTT CTC AAA ATT CGA GTG ACA A 
Tnf reverse: TGG GAG TAG ACA AGG TAC AAC CC 
Cd36 forward:	  TTA ATG GCA CAG ACG CAG CC 
Cd36 reverse:	  TCA GAT CCG AAC ACA GCG TGA 
9.2.15 ELISA 
Tissue samples were lysed in ELISA lysis buffer (50 mM pH7.4 Tris, 5 mM EDTA, 
150 mM NaCl, 1% NP-40 and proteinase inhibitors (Roche)). After homogenization, 
lysate were incubate at 4 C° for 20 mins and centrifuged at 4 C°, 12000 rpm for 10 
min to remove debris. Protein concentrations of the supernatant were determined with 
a BCA protein assay kit (Pierce). ELISA for TGF-β1 and SP-D were performed 
according to the manufacturer’s instructions (R&D). 
9.2.16 Next Generation Sequencing 
Total RNA was isolated from FACS-sorted AMs (≥1.5 × 105 cells) using the RNeasy 
micro plus kit (Qiagen). 100 ng total RNA samples were poly-A selected and used for 
library preparation with TruSeq Stranded mRNA Sample Prep Kit (Illumina, Inc, 
California, USA). Next generation sequencing was performed by the Functional 
Genomics Center Zurich (FGCZ) using the HiSeq 2500 v4 System (Illumina). 
Bioinformatic analysis was performed using SUSHI platform developed by the 
	  70	  
FGCZ. In short, Fastqc for quality control, STAR for mapping, DexSeq for exon 
counts, RSEM for transcript counts, and EdgeR for differentially expressed genes 
(DEG) were done with SUSHI. Gene ontology (GO) analysis by SUSHI and Gene Set 
Enrichment Analysis (GSEA) were performed on DEGs with p < 0.001. 
9.2.17 Quantification and Statistical Analysis  
Statistical analysis was performed using Prism 6 (GraphPad Software). Statistical 
significance was evaluated by Student’s t test or one-way ANOVA. *p < 0.05; **p < 
0.01; ***p < 0.001; ns, not significant. Mean (±SEM) was indicated with horizontal 
lines. N represents number of biological replicates unless otherwise stated. Statistical 
details for each experiment can be found in its corresponding figure legends. 
9.3 Data and Software Availability  
The RNA-seq data is available in the ArrayExpress under the accession code E-
MTAB-6028. 
9.4 Table for Supplementary Materials  	  
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti mouse I-A/I-E clone M5/114.15.2, Alexa 
Fluor 700 
Biolegend Cat#107622; 
RRID:AB_493727 
Anti mouse CD11b clone M1/70, Brilliant Violet 
650 
Biolegend Cat#101259; 
RRID:AB_2566568 
Anti mouse CD11b clone M1/70, Percp-Cy5.5 Biolegend Cat#101228; 
RRID:AB_893232 
Anti mouse CD11c clone N418, PE-Cy7 Biolegend Cat#117318; 
RRID:AB_493568 
Anti mouse CD45 clone 30-F11, APC-Cy7 Biolegend Cat#103116; 
RRID:AB_312981 
Anti mouse CD45 clone 30-F11, Pacific Blue Biolegend Cat#103126; 
RRID:AB_493535 
Anti mouse CD45.1 clone A20, Pacific Blue Biolegend Cat#110722; 
RRID:AB_492866 
Anti mouse CD45.1 clone A20, APC Biolegend Cat#110714; 
RRID:AB_313503 
Anti mouse CD45.2 clone 104, APC-Cy7 Biolegend Cat#109824; 
RRID:AB_830789 
Anti mouse CD45.2 clone 104, PB Biolegend Cat#109820; 
RRID:AB_492872 
Anti mouse CD115 clone AFS98, APC eBioscience Cat#17115282; 
RRID:AB_1210789 
Anti mouse Ly6C, clone AL-21, FITC BD Cat#553104; 
RRID:AB_394628 
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Anti mouse Ly6C HK1.4, Brilliant Violet 605 Biolegend Cat#128036; 
RRID:AB_2562353 
Anti mouse Ly6C HK1.4, Brilliant Violet 711 Biolegend Cat#128037; 
RRID:AB_2562630 
Anti mouse Ly6G clone 1A8, Percp-Cy5.5 Biolegend Cat#127616; 
RRID:AB_1877271 
Anti mouse Ly6G clone 1A8, Brilliant Violet 421 Biolegend Cat#127628; 
RRID:AB_2562567 
Anti mouse Ly6G clone 1A8, PE Biolegend Cat#127605; 
RRID:AB_1236488 
Anti mouse Siglec-F clone E50-2440, PE-CF594 BD Cat#562757; 
RRID:AB_2687994 
Anti mouse CD3 clone 17A2, Alexa Fluor 700 eBioscience Cat# 56-0032-82; 
RRID:AB_529507 
Anti mouse CD45R clone RA3-6B2, PE-Cy7 Biolegend Cat#103222; 
RRID:AB_313005 
Anti mouse CD103 clone 2E7, APC eBioscience Cat# 17-1031-82 
RRID:AB_1106992 
Anti mouse F4/80 clone Cl:A3-1, Alexa Fluor 647 AbD Serotec Cat# MCA497A647; 
AB_1102555 
Anti mouse F4/80 clone Cl:A3-1, Biotin AbD Serotec Cat# MCA497B(B); 
RRID:AB_323893 
Anti mouse CD64 clone X54-5/7.1, PE Biolegend Cat#139304;  
RRID: AB_10612740 
Anti mouse CD24 clone M1/69, Percp-Cy5.5 Biolegend Cat#101824; 
RRID:AB_1595491 
Anti mouse CD24 clone M1/69, Alexa Fluor 488 Biolegend Cat#101816; 
RRID:AB_493482 
Anti mouse CD31 clone 390, FITC Biolegend Cat# 102406; 
RRID:AB_312901 
Anti mouse EpCam clone G8.8, Percp-Cy5.5 Biolegend Cat#118220; 
RRID:AB_2246499 
Anti mouse FABP4 Biotinylated Antibody R&D  Cat# BAF1443 
Anti mouse CD16/CD32 clone 2.4G2 Biolegend Cat#101310; 
RRID:AB_2103871 
mouse IgG1 isotype control clone: MOPC-21 BioXcell Cat# BE0083; 
RRID:AB_1107784 
anti-pan TGF-β1 antibody clone: 1D11.16.8 BioXcell Cat# BE0057; 
RRID:AB_1107757 
   
Chemicals, Peptides, and Recombinant Proteins 
Collagenase type IV Sigma-Aldrich Cat#C5138-1G 
Percoll GE Cat#P4937 
HBSS (with Ca2+/Mg2+) Gibco Cat#14025-050 
HBSS (without Ca2+/Mg2+), Gibco Cat#14170-112 
Dispase Gibco Cat#17105-041 
Oil Red O (Sudan IV) Sigma Cat#O0625 
Immunoselect antifading mounting medium  Dianova Cat# SCR-38447 
DPX mounting medium Sigma Cat#06522 
Hematoxylin Morphisto Cat#10231.01000 
Eosin Morphisto Cat#10177.00500 
DAPI containing immunoselect antifading 
mounting medium  
Dianova Cat#SCR-038448 
immunoselect antifading mounting medium Dianova Cat#SCR-038447 
hTGF-β1 PeproTech Cat#100-21 
GM-CSF Biolegend Cat#576308 
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DMEM PAN Biotech Cat#P04-03500 
Sodium Pyruvate Gibco Cat#11360 
GlutaMAX Gibco Cat#35050-038 
FCS Merck Cat#S0615 
Pen/Strep Gibco Cat#15140-038 
β-Mercaptoethanol Gibco Cat#31350-010 
HEPES Gibco Cat#15630-056 
Proteinase inhibitors Roche Cat#05056489001 
Rosiglitazone Sigma Cat#R2408-50MG 
   
Critical Commercial Assays 
Zombie Aqua Fixable Viability Kit Biolegend Cat# 423102 
Zombie Near-IR Fixable Viability kit Biolegend Cat# 423106 
RNeasy micro plus kit  Qiagen Cat# 74034 
M-MLV reverse transcriptase  Invitrogen Cat# 28025 
SYBR Green  Bio-Rad Cat# 1725124 
BCA protein assay kit  Pierce Cat# 23227 
mouse TGF-beta1 Elisa R&D Cat# DY1679-05 
ELISA for SP-D R&D Cat# DY6839-05 
TruSeq Stranded mRNA Sample Prep Kit  Illumina Cat# RS-122 
   
Deposited Data 
RNA-seq data  E-MTAB-6028 
   
Experimental Models: Organisms/Strains 
ItgaxCre  The Jackson 
Laboratory 
RRID:IMSR_JAX:008068 
Lyz2Cre  The Jackson 
Laboratory 
RRID:IMSR_JAX:004781 
Vav1Cre  Group Manfred 
Kopf 
RRID:IMSR_JAX:008610 
R26CreER  The Jackson 
Laboratory 
RRID:IMSR_JAX:004847 
Cx3cr1CreER  Group Steffen Jung RRID:IMSR_JAX:021160 
Tgfbr2fl/fl  The Jackson 
Laboratory 
RRID:IMSR_JAX:012603 
Tgfb1fl/fl  The Jackson 
Laboratory 
RRID:IMSR_JAX:010721 
Csf2rb-/- (Csf2rbLacZ/LacZ) Croxford et al., 
2015 
Croxford et al., 2015 
Influenza virus (A/Puerto rico/8/1934) Charles River  
   
Software and Algorithms 
GraphPad Prism 6 GraphPad Software N/A 
FlowJo v10 Tree Star https://www.flowjo.com/solu
tions/flowjo/downloads 
Cytobank  Cytobank http://fluidigm.cytobank.org 
   
Other 
22 G x 1.00 Insyte-W™ peripheral venous catheter  BD Cat# 381323 
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